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        25th October 2011 
 
Rt Hon. Theresa May, MP  
2 Marsham Street 
London  
SW1P 4DF 
 
Dear Home Secretary,  
 
The Advisory Council on the Misuse of Drugs (ACMD) committed to 
providing the Government with advice on novel psychoactive substances 
(often colloquially termed „legal highs‟). This is a relatively recent 
phenomenon, exemplified by the drug known as mephedrone. The actions 
by the ACMD and subsequently by the Government on this drug have 
gone some way to reducing the potential harms caused by this substance. 
However, there is more that can be done.  
 
The advent of novel psychoactive substances has changed the face of the 
drug scene remarkably and with rapidity. The range of substances now 
available, their lack of consistency and the potential harms users are 
exposed to are now complex and multi-faceted. In light of this we have 
pleasure in enclosing the Council‟s report.  
 
This report provides advice on high level issues that ACMD believe the 
Government should give careful consideration to in addressing legally 
available psychoactive substances. The report does not purport to provide 
a single solution to the problem, but rather a number of practicable options 
that, in combination, seek to tackle the on-going sale, supply and 
consequential harms.       
 
It is important that the Government recognises that each and every 
department, that has a locus of responsibility in drug issues should both 
take personal ownership and share collective responsibility of the 
recommendations in this report. Tackling the issues that are raised by 
novel psychoactive substances requires a co-ordination of efforts that can 
only be realised by a strategic and co-operative approach. The ACMD has 
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identified lead departments for each of the recommendations that should 
assist and guide the Government in this aim.  
 
The ACMD provides key recommendations in this report on legislation, 
public health, education and research. The key legislative measures are 
primarily concerned with tightening the enforcement of existing legislation 
and moving the responsibility for the supply of novel psychoactive 
substances to the vendors, such that the burden of proof falls to them. The 
ACMD believe it is for vendors to prove that such substances are neither 
analogues of current medicines nor products harmful to consumers in their 
intended form. The ACMD also makes key recommendations around 
public awareness from local to international initiatives.     
 
The production of this report has been greatly aided by valuable 
contributions from a wide range of organisations and experts. The Council 
is particularly grateful to those experts who provided written and oral 
evidence.  
 
We will welcome an opportunity to discuss the report with you in due 
course 
 
Yours sincerely  
 
 
 
 
 
Professor Les Iversen 
Chair, ACMD  
 
 
 
 
Professor Simon Gibbons  
Chair, Novel Psychoactive Substances Working Group  
 
 
 
 
 
 
Cc: 
Lord Henley 
Anne Milton  
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Executive Summary  
 
1.1 The Advisory Council on the Misuse of Drugs (ACMD) was 
requested to consider the issue of Novel Psychoactive Substances 
(hereafter, termed „NPS‟) as one deserving careful and priority 
consideration. This issue has been a priority for the ACMD and of 
this Government1. 
 
1.2 This report provides high level advice to the Government on various 
practicable policy and legislative options that would tackle the on-
going sale, supply and consequential harms associated with NPS 
and considers areas for research.       
 
1.3 The issue of NPS2 (often termed ‟legal highs‟) is not recent, but has 
become prominent due to a range of complex factors, including: 
chemical technologies, market availability, internet supply, trends in 
substance misuse, price and others.  
 
1.4 Generally legally available, NPS fall, broadly, into four categories:  
 
i) Products with names which give no indication of what they 
contain; 
 
ii) Named and specific substances which are designed to be 
similar chemically and/or pharmacologically to known specific 
controlled drugs; 
  
iii) Substances related to medicines; and,  
 
iv) Herbal and fungal materials or their extracts. 
 
The issue 
1.5 While a number of NPS have been controlled under the Misuse of 
Drugs Act 1971, e.g. piperazines including benzylpiperazine (BZP), 
synthetic cannabinoid receptor agonists and cathinones including 
mephedrone, among others, a number of synthetic chemicals 
designed to mimic the action of compounds such as amphetamines 
and ecstasy, or other controlled substances continue to be legally 
available. 
 
1.6 The marketing and sale of NPS is often designed specifically to 
avoid legislation under the Medicines Act 1968 and NPS are 
therefore often marketed as „not for human consumption‟ and may 
variously be described as „plant food‟ or other terms. No safety data 
are provided with the materials and labelling is commonly as 
„research chemicals‟.  
 
                                            
1
 http://www.homeoffice.gov.uk/publications/alcohol-drugs/drugs/acmd1/ACMD-letter-
home-sec-priorities?view=Binary 
2
 See section 2 for a definition.  
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1.7 In the UK NPS are traded openly on the internet and in „head 
shops‟.  This remains a very difficult trade to control. NPS may more 
often than not be purchased from overseas websites. 
 
1.8 A large number of NPS are currently available in the UK from 
several different chemical classes with no data in relation to their 
pharmacology, chemistry, toxicology or safety assessments. The 
potential risk in the human use of such untested substances is 
obvious. 
 
1.9 Reliable data on the prevalence of use or societal impact of NPS 
are difficult to obtain. Surveys of young people suggest that 20 to 
40% have ever tried NPS and in the case of mephedrone (pre-ban) 
one survey indicated 34% had used in the past month, although 
these may be heavily biased samples (see British Crime Survey 
data table 1 & mixmag survey table 2).   
 
1.10 The harms of NPS are multi-faceted and may be physical (intrinsic 
to the drug) or social in nature. Health services are starting to see 
health and other problems caused by regular use of NPS affecting 
NPS users' employment and education. Cases of dependence 
which require detoxification and psycho-social treatment (e.g. GHB 
(gamma-hydroxybutyrate)/GBL (gamma-butyrolactone )3 
dependence) are also presenting to specialist substance misuse 
and other services (sexual health services, youth support services 
etc) (ACMD, 2008).  
 
1.11 There is an upward trend in admissions, due to NPS drug toxicity, 
for both hospital and pre hospital presentations. Most presentations 
show similar characteristics to stimulants such as cocaine, MDMA 
and amphetamine (pers comm, Dr David Wood, Dr Paul Dargan).  
The ACMD believes that particularly when new substances emerge 
that users have no experience of using, this may result in greatest 
harm before knowledge and understanding of a particular drug and 
its effects. 
 
1.12 Further the ACMD understands that most people using NPS are not 
coming to the attention of specialist drug treatment services or 
general health services. Further, most people currently obtain 
information about NPS from their peers or from internet sites where 
drug using experiences are shared. The ACMD remains particularly 
concerned about under 16s using NPS.  
 
1.13 Data from the National Programme on Substance Abuse Deaths 
(np-SAD) shows that there are 42 confirmed mortalities associated 
with one of the first NPS, mephedrone (see annex C).  
 
                                            
3
 Gamma hydroxybutyrate and 1-gamma butyrolactone 
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1.14 Many of the NPS‟s are synthetic amphetamine-like 
pyschostimulants and are likely to share many of the well -
documented adverse effects and dependence liability of the 
amphetamines. It can be predicted that the most potent substances 
are most likely to give rise to a risk of overdose, since the human 
dose is measured in a few milligrams, an amount equivalent to a 
grain of sugar.   
 
Recommendations are listed in brief below for more details see 
chapter 12. 
 
1.15 The UK should be pro-active in developing EU and international 
networks to address the issue of NPS.  
 
1.16 Further, steps should be taken at EU level to encourage source 
countries to halt the manufacture of such substances.  
 
1.17 For the Government to consider how to expedite the process of 
updating the Misuse of Drugs Act 1971 where more minor 
amendments to generic definitions are required e.g. cathinones, 
synthetic cannabinoids, tryptamines, phenethylamines and ketamine 
derivatives.  
 
1.18 The application of the Act would be aided by continued capability 
developments in the area of chemical standards, analytical 
capability and forensic detection of compounds. 
 
1.19 Explore the possibility of new legislation similar to the Analogue Act 
(1986) used in the USA and similar laws in other countries, in 
conjunction with generic definitions of chemical scope.   
 
1.20 The powers available to the MHRA in the European Pharmaceutical 
Directive (Medicines Act 1968) should be fully utilised to prosecute 
the sale of NPS. The burden of proof should be placed upon the 
supplier to establish beyond reasonable doubt that the product 
being sold is not for human consumption and is safe for its intended 
use. 
 
1.21 The powers available in the Consumer Protection from Unfair 
Trading Regulations (2008) (CPRs) and General Product Safety 
Regulations (2005) (GPSRs) should be fully utilised to control the 
trade in NPS. If the Regulations are considered lacking in this 
respect, then thought should be given to amendments so that the 
legislation can be brought to bear.   
 
1.22 Provide resources for research on novel psychoactive substances 
and encourage all research councils to put out calls in these areas.   
 
1.23 Request the Advertising Standards Authority (ASA) to investigate 
claims made by NPS websites. 
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1.24 Continue to strengthen public awareness and education of the 
dangers of using substances for which no safety data exists, using 
the most up-to-date IT methods (FRANK).  The ACMD recommends 
that the government raise public awareness around NPS and 
implements strategies to reduce the demand for NPS 
by including NPS in substance misuse education in schools; 
developing targeted prevention initiatives and also treatment for 
those with acute problems (e.g. within A&E) and dependency. 
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2. Background  
 
2.1. The ACMD was established under the Misuse of Drugs Act 1971 
(hereafter termed the „Act‟) and its purpose is to keep under review 
the drugs situation in the UK and provide advice to ministers. That 
advice may be concerned with; restricting availability, facilities and 
treatment (recovery), promoting co-operation between professional 
and community services, educating the public and promoting 
research.  
 
2.2. This report is concerned with advice on the issue of Novel 
Psychoactive Substances (hereafter shortened to NPS), sometimes 
known as „legal highs‟. NPS are drugs which mimic, or are claimed 
to mimic, the effects of illegal drugs. There is a common, but 
mistaken, perception that because such drugs are not legally 
controlled or banned they are safe. None of them, however, have 
been subjected to anything approaching the stringent testing 
procedures which are required before a new medicine for human 
use is granted a license and, consequently, there is a significant risk 
of short- and long-term adverse effects resulting from their use 
 
2.3. The Home Secretary indicated in correspondence with the ACMD, 
of February 2011, the importance attributed to the issue of Novel 
Psychoactive Substances. The ACMD similarly shares the concerns 
of the Government and considers the issue of newly emerging NPS 
as one which should be afforded careful and priority consideration. 
 
2.4. The media has publicly charted the rise in prevalence of NPS. The 
issue was first brought to the fore in the media with the marketing of 
„Spice‟ (an herbal material adulterated with a synthetic cannabinoid) 
products (Annex B) and subsequent intense interest in mephedrone 
and other compounds. 
 
2.5. The ACMD has previously advised ministers on a number of NPS, 
e.g. BZP, spice and the cathinones (see ACMD reports and Annex 
B).  
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3. Introduction and scope 
 
3.1. The ACMD define NPS as:  
 
„psychoactive drugs which are not prohibited by the United 
Nations Single Convention on Narcotic Drugs or by the Misuse of 
Drugs Act 1971, and which people in the UK are seeking for 
intoxicant use‟.   
 
3.2. Generally legally available, NPS fall, broadly, into four categories:  
 
i) Products with names which give no indication of what they 
contain;  
  
ii) Named and specific substances which are designed to be 
similar chemically and/or pharmacologically to known specific 
controlled, drugs;   
  
iii) Substances related to medicines; and,  
 
iv) Herbal or fungal materials or their extracts. 
 
3.3. The Government has widely disseminated the statement that: 
 
„just because a substance is termed „legal‟ this does not make it 
safe, nor may it be legal‟.  
 
The premises in this statement are true and will be explored in this 
report.   
 
3.4. This report‟s purpose is to provide consideration and advice on 
ways in which the Government can reduce the overall harms of 
NPS, develop options for reducing the demand for, and availability 
of novel psychoactive substances and to provide a more detailed 
consideration of the issue for the future.  
 
3.5. This report is not intended to provide any specific recommendations 
on those NPS that should or could be controlled, (it should not be 
inferred that the NPS mentioned in this report should consequently 
be controlled).  
 
3.6. The report will cover those NPS which are currently used and 
consider: 
i)  The social and physical harms attributed to the use of NPS;   
 
ii) Both UK domestic legislative vehicles e.g. Misuse of Drugs 
Act 1971; Temporary Banning Powers; the Medicines Act 1968 
and Trade Descriptions Act 1968 and the feasibility of 
developing other legislation including „analogue legislation‟ – 
such as that used in the US;  
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iii) Outlining challenges in relation to forensic analyses of NPS; 
and, 
 
iv) Measures to restrict the supply and demand of NPS. The 
report will outline some educational and other measures to this 
objective. 
 
3.7. The report considers where there are gaps in the evidence base 
and in capability where there should be investment and research.     
 
3.8. The importance of this report and its potential value can be 
highlighted with the examples of two case studies: 
 
3.8.1. Mephedrone  
The increase in the use of mephedrone in 2009/10 and its 
widespread marketing across Europe was alarming, particularly for 
the rapidity with which the drug became first choice for users. Its 
detection and identification prompted its consideration by the 
ACMD, who undertook an evaluation of the harms of the drug and 
concluded that it possessed similarities to existing 
pyschostimulants. Consequently, the ACMD advised the 
Government that it should be controlled, under the Act, as a Class B 
substance (for details see Annex B).  
 
3.8.2. 2-DPMP (desoxypipradrol) 
Early analysis indicated that the drug 2-DPMP was being marketed 
as „Ivory Wave‟ in 2010. The ACMD was sufficiently concerned by 
early reports of A&E admissions for this substance to recommend it 
to be subject to controls under the Open General Import Licence in 
October 2010.  The ACMD have reviewed the profile of 2-DPMP 
(ACMD, 2011) and recommended that 2-DPMP and related 
analogues be controlled as Class B substances under the Misuse of 
Drugs Act 1971 (this advice was subsequently accepted by the 
Government). Meanwhile other psychoactive substances have been 
detected in test samples of „Ivory Wave‟. Earlier test samples of 
„Ivory Wave‟ contained the banned cathinone, MPDV 
(methylenedioxypyrovalerone), and more recent analyses have 
detected diphenylprolinol, another pipradrol analogue (which are 
included in the generic definition described above).   
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4. The changing drug scene 
 
4.1. It is important to note that overall drug use is coming down in the UK 
(British Crime Survey 2010/11). However, a significant recent 
development has been the increasing appeal of a range of new and 
easily available NPS.  
 
4.2. The marketing and sale of NPS is often designed specifically to 
avoid legislation under the Medicines Act 1968. NPS are often 
marketed as „not for human consumption‟ and may variously be 
described as „plant food‟, „fish food‟, „room odoriser‟ or other terms. 
No safety data are provided with the materials and labelling is 
commonly as „research chemicals‟.  
 
4.3. Some materials are sold as „legal high‟ products with a trade name 
but no indication of the active ingredients, while others are sold as 
„research chemicals‟ under a specified chemical name. Both are 
often of un-reliable quality. Analysis of products has shown that the 
contents of branded products can change markedly from batch to 
batch, while the „research chemicals‟ often turn out to be other than 
the chemical declared (see paragraph 5.2 below).  
 
4.4. The chemists responsible for developing these new products have a 
sophisticated knowledge of the chemical/pharmacological scientific 
literature and the law. The example of mephedrone followed within a 
few months by naphyrone demonstrates how quickly this new 
industry can adapt to changes in the law to find markets to exploit. 
 
4.5. Evidence suggests that the majority of NPS are currently imported 
from China - primarily in air freight and the post. There is a 
significant challenge for border agencies in identifying the true 
nature of the substances that are presented as „white powders‟ and 
declared at importation as a variety of chemicals - many of which 
are wrongly described. Some of the materials are banned, some 
subject to licensing, some are known as psychoactive substances 
(and legal), and some are not known and may or may not be novel 
psychoactive substances of misuse in the future. 
 
4.6. Selecting consignments for examination at the border is presently 
conducted on a risk based approach - it is impossible to examine or 
scan all freight and parcels.  Once a consignment is selected; 
specially trained officers, expensive health and safety equipment 
and new technologies are often needed to conduct the examination.  
Where the substances are found and cannot be identified, samples 
can be sent to forensic scientists for analysis and identification.  
 
4.7. Once in the UK, legal psychoactive substances are traded openly 
on the internet and also via dealers on the streets and in clubs and 
pubs. Purchases of NPS may also be made from non-UK internet 
sites and then supplied from overseas (both EU and non EU).  As 
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the sale and distribution is in „legal‟ products it is a very difficult 
trade to influence or control.  
 
4.8. The growth in the NPS market has brought a different type of „drug 
dealer‟ with entrepreneurs seeing the business opportunity whilst 
the substance remains „legal‟. This has meant that once a 
substance has entered the drug scene the market can be very 
quickly saturated with the new drug. Many people importing these 
new substances appear to have had no previous involvement in the 
illicit drug trade and are just in it to make a „quick buck‟. They have 
included students who have set up websites to supply nationally and 
who also supply the local student population. 
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5. Harms 
 
5.1. The harms of the use of NPS are multi-faceted and may be physical 
(intrinsic to the drug) or social in nature. The ACMD has considered 
the harms of previous, groups of NPS in its reports on „Spice‟ (the 
synthetic cannabinoid receptor agonists) (ACMD, 2009a), 
mephedrone (ACMD, 2009b), the naphthylpyrovalerone analogues, 
including naphyrone (ACMD, 2010a) and 2-DPMP – 
desoxypipradrol (ACMD, 2010b).    
 
5.2. Test purchasing of NPS and forensic studies have shown that the 
contents of products are variable (Davies et al., 2010; Ramsey et 
al., 2010; Brandt, et al., 2010 a,b,c; SOCA, 2011). Despite claims, 
NPS marketed as one substance often contain something different 
and the content of a product may vary from month to month. 
Furthermore, some substances described and sold as „legal highs‟ 
in fact contain controlled substances - in particular cathinones such 
as mephedrone, butylone or fluoromethcathinone and piperazines 
such as benzylpiperazine, fluorophenylpiperazine or 
chlorophenylpiperazine. A recent report of forensic analysis of 
seized samples of NPS indicated that 19% of samples tested 
contained a controlled substance (SOCA, 2011).  
 
5.3. There are two consequences of this.  
 
1. The variation in content of these products, with the presence of 
psychoactive substances of variable potency and adverse 
effects puts users at risk of increased acute harm and toxicity 
associated with their use; and, 
2. Users, particularly young people, who are in possession of what 
they think are „legal highs‟ may well be in possession of 
controlled substances and could face the prospect of being 
subject to prosecution and a potential criminal record if found in 
possession of them by the Police. 
 
5.4. More recent studies have shown that NPS may contain only 
caffeine. Caffeine at the doses found in these studies (1g per 
packet) can result in significant toxicity, particularly if the user takes 
the product thinking that it contains an NPS rather than caffeine 
(Davies 2011).  
 
5.5. Most legally available novel psychoactive substances are sold with 
no data regarding their chemistry, pharmacology or toxicology, no 
safety assessments and no administration instructions. The risks 
inherent in using such substances that have not been subjected to 
any safety assessments are obvious.  
 
5.6. Use of NPS (both alone and with other substances) can result in 
acute toxicity and serious harm. The use of NPS can also result in 
young people and adults putting themselves in situations where they 
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may be vulnerable or at risk of other harms (e.g. through collapse, 
intoxication, etc) including accidents and being victims of crime (e.g. 
sexual or physical assault).  
 
5.7. Many of the NPS‟s are synthetic amphetamine-like 
pyschostimulants and are likely to share many of the well 
documented adverse effects and dependence liability of the 
amphetamines. It can be predicted that users of the most potent 
substances are most likely to be at risk of overdose and associated 
acute toxicity since the human dose is measured in a few milligrams 
(i.e. the equivalent of a few grains of sugar).   
 
5.8. The paucity of information on the pharmacology and toxicology of 
most NPS makes it hard to understand their possible dangers, or 
even to know what substances are contained in products branded 
as „Ivory Wave‟ or „Meow Meow‟.  For example, forensic analysis 
has revealed that the psychoactive substance present in „Ivory 
Wave‟ has varied between samples. Analysis of test purchase 
samples and biological samples from individuals presenting to 
hospital with acute toxicity associated with NPS demonstrate that 
this is a rapidly changing market; analysis shows that numerous 
new legal drugs are being taken within a number of different classes 
and groups of drugs.  
 
5.9. Acute recreational drug toxicity is a common reason for presentation 
to both hospital and pre-hospital medical services. It appears that, 
generally, the pattern of toxicity associated with NPS is broadly 
similar to that seen with classical stimulant recreational drugs such 
as cocaine, MDMA and amphetamine.  
 
5.10. Obtaining information from hospitals on the patterns of acute toxicity 
associated with NPS can be difficult for a number of reasons:  
 
i) Emergency Department and hospital staff are often not 
aware of these agents when they first become available and 
so they may be misrepresented in the medical notes. This 
was widely seen when patients first presented to hospital with 
self-reported mephedrone toxicity; some healthcare 
professionals were unaware of mephedrone and therefore 
recorded this in the notes as the synthetic opiate methadone. 
Although mephedrone and methadone have similar sounding 
names, they have very different pharmacological and 
toxicological actions.  
 
ii) Healthcare professionals may contact the National Poisons 
Information Service (NPIS) for support in managing patients 
with acute recreational drug toxicity. The information collated 
by NPIS on acute NPS toxicity is reliant on the accuracy of 
the information provided to them by the treating physician.  In 
addition, there may be a delay in on-line TOXBASE entries 
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being created on NPS as this requires the NPIS to be aware 
of the new drugs, and their associated harms to be able to 
draft a new TOXBASE entry. 
 
iii) Hospital admissions are coded using an International 
system overseen by the World Health Organisation which is 
known as ICD-10. A number of studies have shown that this 
system is poor for coding acute recreational drug toxicity as a 
whole and even poorer for NPS as these drugs are not 
included in the coding system (Wood et al., 2011a; Shah et 
al., 2011). Furthermore, UK hospital admission data collated 
through the Hospital Episode Statistics (HES) based on the 
ICD-10 coding system currently only captures those patients 
that are admitted to hospital and does not include data on 
those discharged directly from the Emergency Department. 
The experience of Guy‟s and St Thomas‟ NHS Foundation 
Trust Clinical Toxicology Service is that up to 50% of patients 
with acute recreational drug toxicity are discharged directly 
from the Emergency Department. Therefore, for a number of 
different reasons, the HES dataset significantly under-
estimates the true burden of acute toxicity associated with 
the use of NPS.  
 
iv) Toxicological screening of blood and/or urine samples in 
patients presenting to hospital with acute recreational drug 
toxicity is not routinely undertaken as these patients are 
managed on a clinical basis and the results of 
comprehensive toxicological screening will not be available in 
a time-frame to be able to influence management decisions. 
Screening is generally only undertaken in specialist clinical 
toxicology centres for research purposes.  
 
v) Finally, when toxicological screening is undertaken the 
ability to detect NPS depends on the expertise of the 
laboratory undertaking the analysis and the 
comprehensiveness of their analytical libraries of reference 
compounds.  
 
5.11. The initial information on the patterns of acute toxicity and adverse 
effects associated with the use of NPS often comes from 
unsubstantiated internet based user discussion forums. Subsequent 
reports typically come from specialist hospitals with clinical 
toxicology services with an interest in acute recreational drug 
toxicity and specifically in NPS acute toxicity. Initially, these are 
often single case reports or case series which may attribute toxicity 
to the „legal high‟ based on self-reported use rather than analytical 
confirmation; these reports come both Emergency Departments, 
clinical toxicology services and poisons information services (Wood 
et al., 2011b; Regan et al., 2010; James et al., 2010; Centres for 
Disease Control and Prevention, 2011; Personne and Hulton, 2008). 
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Publication of case reports / small case series is becoming more 
difficult and there is the potential that this may become a less 
available source of information on this topic. Analytical confirmation 
of the NPS  responsible for toxicity is essential because a number of 
studies have shown that the content of various products purchased 
both from the Internet and street level drug dealers is variable and 
unreliable (Davies et al., 2010; Ramsey et al., 2010; Brandt et al., 
2010a,b). Therefore, attributing toxicity to a particular substance 
based on self-reported use may result in an inaccurate 
representation of the toxicity associated with individual chemicals.  
 
5.12. Despite these barriers, specialist clinical toxicology services working 
together with analytical toxicology laboratories with the necessary 
equipment and expertise to be able to screen for novel psychoactive 
substances can provide detailed data on the patterns of toxicity 
associated with NPS. In the last 4 years the clinical toxicology 
service, at Guy‟s and St Thomas‟ NHS Foundation Trust in South 
East London, has detected 14 NPS in patients presenting to hospital 
with acute „recreational‟ drug toxicity (Wood et al., 2007; Dargan et 
al., 2008; Lidder et al., 2008; Wood et al., 2008a, Ovaska et al., 
2008, Wood et al., 2008b; Wood et al., 2009; Wood et al., 2010 a,b; 
Wood et al., 2011c). These include drugs from a number of different 
classes including the cathinones (e.g. mephedrone; methylone; 
methylenedioxypyrovalerone (MDPV) and butylone); piperazines 
(e.g.1-benzylpiperazine, trifluoromethyl-phenyl-piperazine); the 
pipradrols (D2PM diphenyl-2-pyrrolidinemethanol); and 
benzodifurans (e.g. Bromo-DragonFLY). A number of other groups 
have also reported cases or small case series of acute toxicity 
associated with analytically confirmed NPS (Derungs et al., 2011; 
Sammler et al., 2010; Thorlacius et al., 2008, Gee et al., 2008; Gee 
et al., 2010/a,b). Overall, the pattern of toxicity seen with NPS is 
significant and similar to that previously described in association 
with classical stimulant recreational drugs such as cocaine, MDMA 
and amphetamine. The clinical features seen in patients with acute 
toxicity associated with NPS include agitation, psychosis, delirium, 
tachycardia, hypertension, chest pain and seizures.  
 
5.13. Some health services have started to see acute health and other 
problems caused by the chronic use of NPS. In addition to 
immediate acute health effects, they can have secondary effects 
and impact on NPS users‟ employment and education. For the 
formerly available NPS gamma-hydroxybutyrate (GHB) and gamma-
butyrolactone (GBL) there have been reports of cases of 
dependence which require detoxification and psycho-social 
treatment.  
 
 
5.14. These levels of problematic use require health professionals to 
develop treatment interventions to enable NPS users to try and stop 
use of these substances becoming regular or problematic, and 
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treatment for those with dependence or ongoing health problems 
caused by NPS.   
 
5.15. Data from the National Programme on Substance Abuse Deaths 
(np-SAD) shows that  42 mortalities have been confirmed as 
associated with one of the first NPS, mephedrone (see annex C).  
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6.  Use and societal impact  
 
6.1. The availability and use of NPS is such a recent phenomenon that 
reliable data on prevalence of use and societal impact is difficult to 
obtain and, in many cases, is not available. 
 
6.2. In July 2011, the British Crime Survey (BCS) reported its annual 
household survey findings for 2010 when mephedrone and other 
cathinones were added for the first time (British Crime Survey, 
2011). This has provided the first national prevalence figures on 
these compounds. Table 1 shows that in 2010, the use of 
mephedrone (1.4%) was at a similar level to ecstasy use (1.4%) 
among those aged 16 to 59 (the third most used drug within this age 
group). For those aged 16 to 24, mephedrone use (4.4%) was at a 
similar level of use as powder cocaine (4.4%; the second most used 
drug amongst young people.  
 
Table 1: Proportion of 16 to 59 year olds by age band reporting last 
year use of recently classified drugs, 2010/11 (BCS, 2011). 
 
Percentage       England and Wales, BCS 
       Adults aged 16 - 59 
 
Substance All Adults aged 16  
to 24 
Adults aged 25 to 
59 
Spice (and other 
cannabinoids) 
0.2 0.4 0.1 
BZP 0.1 0.2 0.0 
GBL/GHB 0.0 0.1 0.0 
Khat 0.2 0.3 0.1 
Mephedrone 1.4 4.4 0.6 
    
Unweighted base4 27,450 3,667 23,783 
4 Base numbers relate to Spice use. Bases for other drug measures will be similar 
 
6.3. Dargan et al (2010) conducted a survey of mephedrone use in 
1,006 individuals in schools, colleges and universities in an area of 
Scotland. The survey data were collected in February 2010, two 
months prior to the UK control of substituted cathinones in April 
2010. Lifetime prevalence was 20%, ranging from 23% having tried 
it just once through to 4% reporting daily use.  
 
6.4. Mixmag dance music magazine and associated website 
“DontStayIn” (surveygizmo.com) conducts annual online surveys 
with a sample of its readers. Data for the 2010 survey were 
collected in late 2009, several months before the controls on 
mephedrone were implemented. The 2011 Mixmag survey was 
conducted about six months after legislation was introduced, 
thereby allowing a comparison in mephedrone before and after 
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control. Two key limitations to the study are that firstly, it is a self 
selecting online sample and therefore unrepresentative of either the 
general population or the clubbing community and secondly, 
because it is a cross sectional rather than longitudinal survey the 
results are not directly comparable from year to year as the 
composition of the sample will slightly alter. However, the Mixmag 
brand has considerable loyalty amongst clubbers, evident in the 
number of respondents who trust enough to give their mobile phone 
number for follow up interview.  
 
6.5. The findings on mephedrone use in 2010 and 2011, from the 
Mixmag survey (Mixmag, 2011), are summarised in tables 2 and 3 
below, showing that recent (past month) mephedrone use fell by 
about one third after the ban was introduced. In terms of price and 
purity, users reported that the price of mephedrone had roughly 
doubled from about £10/g to about £20/g from late 2009-late 2010, 
with a shift from purchasing from websites to purchasing from 
dealers and most users now suspecting that the mephedrone they 
consume has been adulterated with other agents. The extent of the 
street market is not comparable to the previous internet trade, 
unsurprisingly, with the proportion of users reporting easy access to 
the drug halving between late 2009 and late 2010. 
 
Table 2. Use of mephedrone. Self reported data from the Mixmag 
survey (Mixmag, 2011)  
 
Use 2010 (pre-ban) 2011 (post ban) 
Lifetime Use 42% 61% 
Past year use 37% 51% 
Past month use  34% 25% 
Availability (easy or very easy to 
obtain mephedrone) 
75% 38% 
 
Table 3. Sources of supply of mephedrone, price and whether cut. 
Self reported data from the Mixmag survey (Mixmag, 2011) 
 
Supply 2010 (pre ban) 2011 (post ban) 
Websites 33% 1% 
Dealers 24% 58% 
Price £12.20/g £19.30/g 
Suspect it was cut 30% 80% 
 
6.6. An online survey of over 1,000 mephedrone users recruited from 
forums which attract experienced drug users (Carhart-Harris et al., 
2011) reported that 30% stockpiled mephedrone in anticipation of 
ban; 64% said they used mephedrone less now it was illegal and 
47% said mephedrone was noticeably less available after the ban.  
 
6.7. In terms of displacement, 49% said that they would use more 
MDMA now that mephedrone was banned. The survey also 
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reported a range of concerns arising from mephedrone use with 
13% of users saying they said or did things that they later regretted 
after taking the drug (Carhart-Harris et al., 2011); 14% feeling 
unable to stop taking mephedrone until they had used up all of their 
supplies; 11% reporting very strong cravings for mephedrone after 
having run out of stock and 14% describing it as very addictive.  
 
6.8. Both the Mixmag survey (Mixmag, 2011) and the Carhart-Harris et 
al (2011) survey are limited by their design: they recruited self 
selecting samples of internet users who we might anticipate to be 
unrepresentative of the general population and disproportionately 
drug-experienced given the content of the websites on which the 
surveys were advertised. 
 
6.9. A series of 3 surveys conducted in „gay-friendly‟ dance clubs in 
South London with a convenience sample of club customers found 
that mephedrone had leapfrogged over cocaine and ecstasy to 
become the most popular drug on the fieldwork night despite having 
been controlled over two months prior to the surveys,(Measham et 
al, 2011a). Although overall levels of drug use are much higher 
amongst this sample of predominantly gay clubbers than in the 
British Crime Survey, the ranking of drugs – mephedrone, then 
cocaine, then ecstasy – reflects the findings of the British Crime 
Survey regarding self reported past year drug use amongst young 
adults, discussed above. Furthermore, there was evidence that an 
illegal street market had developed in mephedrone both inside and 
outside the South London dance clubs. However, there was little 
evidence of displacement to so-called second generation legal highs 
such as NRG-1, whose unknown content and misbranding were 
raised as concerns by Brandt et al (2010). 
 
6.10. In the north west of England, surveys have been conducted with 
convenience samples of customers in the night time economies of 
four towns and cities in Lancashire in late 2010, more than six 
months after mephedrone and other substituted cathinones were 
banned (Measham el at., 2011a). Levels of self reported previous 
and current mephedrone use were much lower amongst these night 
time economy (predominantly bar) customers than amongst 
clubbers.  
 
6.11. Also noted in these Lancashire night time economy surveys was the 
distinct local terminology for legal highs – white powders are known 
locally as „Bubble‟ – with users unclear about the content or the 
legal status of this drug (Measham et al 2011b). The researchers 
noted that many users appeared to be uncertain of the content of 
„Bubble‟ but moreover, seemed unconcerned by this. 
 
6.12. The number of different classes of NPS makes predictions as to 
which will have the greatest impact and popularity uncertain, 
nevertheless NPS use appears firmly embedded in the UK drug 
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scene. It is highly likely that NPS with similar levels of popularity to 
mephedrone will appear in the future.   
 
6.13. In applying the Misuse of Drugs Act 1971 to NPS it is important to 
understand that such action may have unintended harmful 
consequences – as described in the Demos/UK Drug Policy 
Commission report (2011). In addition to criminalising users, a 
criminal black market may emerge to supply the drug, with the 
temptation to introduce potentially harmful adulterants – as appears 
to have happened for mephedrone.  These adulterants include 
caffeine, lidocaine, benzocaine and other substances commonly 
found in classical recreational drugs such as cocaine. The 
adulterants may have their own inherent toxicity that can be additive 
to the toxicity related to the NPS. 
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7. Measures to reduce supply 
 
Use of the Misuse of Drugs Act 1971 
7.1. The ACMD consider that the Act should be the primary legislation 
that Government uses to tackle supply side activity. However, the 
Act, and indeed other forms of legislation, can only be brought to 
bear if there is adequate capability and opportunity for detection.  
 
7.2. Many new drugs are variations around central chemical backbones. 
The ACMD previously recommended generic controls to cover any 
closely related, harmful analogues. However, such generic 
definitions cannot cover all potential analogues, nor are they 
intended to. There have been recent examples (cathinones and 
synthetic cannabinoids) where analogues not covered by the 
original generic scope have been developed and marketed as NPS. 
In such cases, it would be advantageous to have a system whereby 
the Act could be updated, not by a separate definition, but as an 
update of the present or generic definition. At present, some families 
of drugs have layers of interrelated Statutory Instruments making 
the legislation difficult to navigate.  
 
7.3. The detection of NPS is the single most limiting factor in the use of 
the Act to bring its penalties to bear on the issue. The two elements 
that comprise detection are firstly capability to analyse for a given 
substance and secondly detection of the drug at the point of import 
and through the supply chain to possession. Sophisticated methods 
of chemical analysis are needed to detect and identify these novel 
substances, for many of which no standard detection tests are 
available. 
 
7.4. The ACMD recognise the work of the Home Office under the 
Forensic Early Warning System (FEWS) that seeks to address two 
major issues: firstly, identifying new compounds of use and 
developing reference standards and secondly, developing 
technologies for identification and enforcement purposes.  
 
7.5. The ACMD are also aware of the Home Office‟s development of the 
Drug Early Warning System project (DEWS). This project aims to 
develop networks and links between evidence providers so that 
information on NPS can be shared and disseminated.  
 
Open General Import licence - UK Border Agency and Novel 
Psychoactive Substances 
7.6. The UK Border Agency (UKBA) is responsible for ensuring that the 
UK border is secure by maintaining border controls through working 
with other UK law enforcement agencies, particularly SOCA and 
other international partners, to intercept drugs before they reach the 
UK border. The UK Border Agency is responsible in enforcing the 
bans under the Open General Import Licence (OGIL).  
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7.7. Unless a Home Office Drug Licence is held, or a specific exemption 
within the Act exists, drugs controlled under the Act are prohibited 
from importation, thereby becoming an assigned matter for UKBA 
under the provisions of the Customs and Excise Management Act 
1979, in respect of which enforcement activity can be undertaken. 
When a new psychoactive substance falls under the control of the 
Act, UKBA must treat that drug in exactly the same way as other 
controlled drugs. The drug can be seized only when imported 
improperly in contravention of a particular prohibition.  
 
7.8. The control of compounds provides UKBA, and other enforcement 
agencies, the powers to intercept and, following confirmatory 
analysis, destroy the consignment at importation. Table 4 presents 
seizures by the UK Border Agency from 16 April 2010 to 31 August 
2011. 
 
7.9. In 2010 the ACMD recommended that desoxypipradrol be subject to 
restrictions placed upon it by importation under the Open General 
Importation Licence (Import of Goods (Control) Order 1954. This 
allows for an import ban but no penalties for possession.  
 
Table 4. Seizures of recently banned substances by the UK Border 
Agency from 16 April 2010 to 31 August 2011. 
 
Drug Number of 
seizures 
Weight (Kilos) 
(Litres) 
Mephedrone (and 
related cathinones) 
(16/4/10 –30/06/11) 
 
71 184kg 
Naphyrone (23/7/10- 
30/06/11) 
 
6 124.4kg 
GBL,  (01/04/10 – 
31/08/11) 
 
24 15.15 (L) 
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Police enforcement and the criminalisation of Young People 
 
7.10. NPS present a particular challenge to the Police as many of the 
substances are white powders that resemble current controlled 
drugs. Added to this, the Police are also aware that many of the 
novel psychoactive substances contain controlled substances and 
without the assistance of accurate field testing devices, people in 
possession of substances are arrested on suspicion of possessing a 
controlled substance. The result will be either: 
i) Detention in Police cells, interviewed then bailed pending 
forensic analysis and released from bail once analysis shows it 
to be a „legal substance‟ 
 
ii) As above but charged with possession when analysis shows 
the presence of a controlled drug.  
 
7.11. As well as the potential waste of Police resources of investigating a 
substance which is not controlled, there is the very real problem of 
young people being criminalised through the possession of what 
they thought was a legal substance. Interactions between Police 
and young people have made it clear that the belief that these 
substances are „legal and therefore safe‟ is the main driver for trying 
them. 
 
7.12. As discussed in Chapter 4 the NPS market has introduced a new 
type of dealer and with it a new type of importer whom at this time, 
appear to be outside of the normal Organised Crime network. They 
are, nevertheless, making substantial profits and there have been 
Police operations against large-scale importers. However, such 
operations are hugely resource intensive, and have far from certain 
outcomes. There are many products sold by these importers and 
subsequently seized by Police, but the financial cost of submitting 
forensic samples to identify those that are controlled is very 
discouraging when considering future operations against NPS 
suppliers. 
 
Medicines Act – Medicines Healthcare products Regulatory Agency 
(MHRA) and NSP 
7.13. In addition to the Act, there are a number of measures that should 
be explored for the purposes of supply reduction. In the main this is 
focussed on other existing legislation outside of the Act such as 
Trading Standards, (consumer products regulations) and the 
Medicines legislation. The DEMOS / UK Drugs Policy Commission 
report (2011) also proposes use of consumer protection by existing 
legislation. 
 
7.14. The Medicines Act 1968 is legislation within the portfolio of the 
Department of Health; this is now mainly based on the European 
Pharmaceutical Directive 2001/83/EC. The Directive is designed to 
ensure that only medicinal products with the appropriate 
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authorisation are advertised, sold and supplied in Member States. 
The licensing processes set out in the Directive mean that products 
meet relevant standards of safety, quality and efficacy (or traditional 
use for traditional herbal medicines). 
 
7.15. If a product falls outside the definition of a medicinal product it is not 
covered by the medicines legislation. The responsibility for 
classifying products as medicines devolves to individual member 
states using the definition contained in Article 1 of the 
Pharmaceutical Directive 2001/83/EC. Guidance on how to interpret 
the definition has been given by the European Court of Justice in a 
number of Judgements over the years. In the UK the MHRA has 
issued guidance on this in Guidance Note 8 A guide to what is a 
medicinal product which is available from the MHRA website. 
 
7.16. Article 1 of Directive 2001/83/EC defines a medicinal product as: 
 
“Any substance or combination of substances presented as having 
properties for treating or preventing disease in human beings 
 
Any substance or combination of substances which may be used in or 
administered to human beings either with a view to restoring, correcting 
or modifying physiological functions by exerting a pharmacological, 
immunological or metabolic action, or to making a medical diagnosis”. 
 
7.17. A product does not have to satisfy both parts of the definition to be a 
medicine, either is sufficient. A product has to be presented for 
human use in order to be considered under medicines legislation. 
 
7.18. When considering substances of abuse or NPS the MHRA is not 
aware of any products being presented to treat or prevent disease. 
So far the MHRA has not issued any determinations under the first 
part of the definition in relation to products which might be regarded 
as substances of abuse or novel psychoactive substances.  
 
7.19. When looking at products under the second limb, the MHRA has to 
demonstrate that the product has a significant effect on human 
physiological functions through a pharmacological, immunological or 
metabolic action. This approach has been set out clearly in a 
number of Judgements from the European Court: 
 
“The pharmacological properties of a product are the factor on the 
basis of which the authorities of the Member States must ascertain, 
in the light of the potential capacities of the product, whether it may, 
for the purposes of the second subparagraph of Art 1(2) of Directive 
2001/83/EC, be administered to human beings with a view 
to…restoring, correcting or modifying physiological function in 
human beings.” HLH Warenvertriebs, 2005  
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7.20. Because of the European Court‟s approach the MHRA has had 
significant difficulties in classifying substances of abuse or novel 
psychoactive substances where data of suitable quality on the 
function and effect of the ingredients at the level contained in the 
product does not exist. The onus in cases of classification is on the 
MHRA to prove that a product has a significant effect, not for the 
person supplying the product to show that it doesn‟t. Because the 
Pharmaceutical Directive is not designed to regulate substances of 
abuse, products which are not presented for human use or which 
are presented for human use, but where there is no evidence of 
significant effect cannot be classified as medicines under the 
second part of the definition of a medicinal product.  
 
7.21. Evidence for actions on human drug receptor or other targets in vitro 
may in future be obtained from collaboration currently being initiated 
with the US National Institute of Mental Health Psychoactive Drug 
Screening Programme, which will provide data from a wide range of 
such drug targets, and other biological research.  
 
7.22. In the case of NPS, logic, reason and analysis to date says and 
demonstrates that many are being sold and used for the express 
purpose of their psychoactive effect (otherwise they wouldn‟t sell). It 
is somewhat perverse that the medicines legislation, set out to 
protect users from harmful products, has been presented to the 
ACMD as having little or no leverage in this area.  
 
Consumer Protection Legislation (2008) and General Product Safety 
Regulations (2005) and Dangerous Substances and Preparations 
(Safety) Regulations (2006) – Business Innovation and Skills and NPS 
7.23. The Consumer Protection from Unfair Trading Regulations 2008 
(CPRs) prohibits the use by traders of unfair commercial practices in 
connection with the promotion, sale or supply of goods and services 
to or from consumers. The purpose of the CPRs is to protect the 
economic interests of consumers. The CPRs are subject to criminal 
and civil enforcement by the Office of Fair Trading and local 
authority trading standards officers. 
 
7.24. Unfair commercial practices include:  
 
i) Making false or deceptive statements; and;  
 
ii) Omitting, hiding or providing unclear information which the 
average consumer needs in order to make an informed decision, 
where (in either case) this causes the average consumer to take a 
different decision.   
 
7.25. Matters in respect of which false statements may breach the CPRs 
could therefore include statements that products would be effective 
as plant food or bath salts (if they would not) and statements that 
products originated in the EU (if they did not). 
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7.26. An example of an omission which could breach the CPRs could be 
a failure to state that a product could be damaging to human health. 
A clear statement that a product is not for human consumption 
would normally avoid the risk of such an omission. Such a 
statement might not be so effective if other statements by the trader, 
or the surrounding circumstances, created an overriding impression 
that the product was in fact intended to be ingested by the 
consumer notwithstanding the first statement. In that case the first 
statement might be seen as a sham and could breach the CPRs. 
 
7.27. In each of these cases there is no breach of the CPRs unless the 
average consumer is misled by the false statement or the omission 
into taking a different decision. Where a commercial practice is 
directed to a particular group of consumers, reference to the 
average consumer is to be read as the average member of that 
group. 
 
7.28. The purpose of the GPSR is to ensure that consumer products 
placed on the market, or offered or agreed to be placed on the 
market, or supplied or offered or exposed or possessed for supply, 
must be safe (the general safety requirement - regulation 5). The 
onus of ensuring safety is on the producer or distributor who is 
therefore liable if the GPSR are breached (see offences under 
regulation 20 of the GPSR).  
 
7.29. In the context of psychoactive drugs sold as plant food or bath salts 
or other consumer product, there would be a breach of the GPSR if 
the producer or distributor placed the product on the market or 
supplied it intending it to be ingested and knowing this ingestion was 
dangerous to human health or safety. The ACMD considers that 
products are knowingly being supplied, in head shops and marketed 
on the internet, for human consumption. In addition, it is known that 
these products have a psychostimulant effect and can, in larger 
quantities, be harmful to health.  
 
7.30. This is exemplified by those products sold as plant food which have 
clear instructions on them and provide a „dose for the plants‟, or 
„warnings to gardeners‟. Indeed, some websites even offer to sell 
analytical balances so that the user can measure a suitable dose of 
„plant food‟; others offer advice on adverse consequences of 
accidental ingestion of „plant food‟.   
 
7.31. The ACMD does not believe such thin veneers of legitimacy should 
be an impediment to the legislative system and be accepted when 
the health of individuals is at risk.  
 
7.32. Offences under the GPSR include the failure to provide appropriate 
information to consumers on inherent risks; failure to adopt 
measures which enable the receipt of information about risks posed 
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by products and to deal with such risks; and failure to monitor safety 
of products placed on the market. Thus if a distributor who was 
made aware or had reason to suspect that the plant food he was 
selling was in fact psychoactive drugs, that would be unsafe. 
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8. Measures to Reduce Demand  
 
8.1. The UK Drug Strategy (2010) has two overarching aims which are: 
 “reduce illicit and other harmful drug use; and, 
 increase the numbers recovering from their dependence” 
 
It recommends that demand for illegal drugs is reduced by: 
 
“…creating an environment where the vast majority of people who have 
never taken drugs continue to resist any pressures to do so, and 
making it easier for those that do to stop. This is key to reducing the 
huge societal costs, particularly the lost ambition and potential of young 
drug users.” 
 
8.2. NPS present particular issues and challenges for demand reduction 
interventions. From analysis of trends in NPS use, it is apparent that 
those who use NPS are mainly young people or young adults 
(British Crime Survey 2011) who are experimenting or trying to 
enhance experiences (mainly at social events), or are those 
participating in clubbing and music events such as festivals (Mixmag 
Survey) NPS use is rarely ‟dependent‟, though it can cause acute 
harm as discussed in previous chapter and often features mixing 
different drugs together and drinking alcohol. 
 
Demand reduction 
8.3. Demand reduction strategies for other types of substance misuse 
which could be applied to NPS include education, prevention, and 
treatment interventions. The evidence base that treatment can 
reduce and stop drug misuse is good. `Drug misuse and 
dependence: UK guidelines on clinical management‟ (2007) states 
“the effectiveness of well delivered evidence-based treatment for 
drug misuse is well established. UK and international literature 
consistently shows that drug treatment covering different types of 
drug problems…..impacts positively on levels of drug use”.  The 
evidence for education and prevention in reducing demand is 
weaker, though some interventions have been shown to increase 
knowledge and delay the onset of use thus reducing potential 
harmful use (Wenzel et al 2009).  
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9. Public health messages  
 
9.1. It is vitally important that there is provision of accurate public health 
messages on NPS to allow potential users to understand the 
choices that they are making and the harms associated with NPS. 
Users may be unaware of the risks that they are taking with such 
substances. Existing mechanisms for delivering public health 
messages and drug education should include reference to NPS 
including public campaigns e.g. FRANK and public information 
campaigns.      
 
9.2. There are health issues associated with NPS which particularly 
stem from the array of available compounds and, as 
aforementioned, the lack of consistency in product content and 
quality (see chapter 5). This array of compounds complicates the 
ability to provide clear messages on any given product – though 
presents opportunities to highlight the potential harm of taking 
unknown and potentially harmful substances. 
 
Drug education and prevention 
 
9.3. The ACMD supports the inclusion of NPS in universal drug 
education programmes in schools alongside other substances and 
over the counter medicines to increase knowledge and awareness 
of harms of NPS. The ACMD concurs with the previous DFEE 
guidance `Protecting Young People‟ (1998) which stated that 
research shows that;   
 The impact of drug education on drug using behaviour has been 
shown to be limited. Drug education alone is unlikely to prevent 
young people from ever experimenting with drugs.  
 „Just Say No‟ and „shock/ scare‟ approaches are likely to be 
ineffective and may even be counterproductive.  
 Good quality drug education can impact on changes in specific drug 
using patterns and reduce the use of drugs and associated 
problems for young people.  
 Drug education can contribute towards decreased harm and 
increased safety for young people, their families and communities.  
9.4. The ACMD are also aware of the need to provide on-going and 
regular education and training on NPS to schools and youth 
services in order to keep abreast of changes in patterns in drug use 
– in order to be able to maximise drug education opportunities in 
schools and youth services. In addition there is also requirement to 
provide education on NPS to parents and families. The ACMD 
therefore consider that there are a number of areas where drug 
education and prevention strategies should be developed to align 
NPS with other substances. 
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9.5. The ACMD consider that innovative and bold use of new 
technologies which are used by young people and young adults 
including social networking sites, multimedia, smartphone 
applications and interactive websites may maximise opportunities to 
reach these populations. Educational `packages‟ using these 
methods and ICT technology may reach a range of groups who are 
thinking of using, or using NPS. If these media were used - it would 
be essential to ensure the information and advice provided is factual 
and evidence-based which outlines potential harms, challenges use 
and directs users to help but which does not preach or moralise. 
 
9.6. Targeted prevention 
 
9.7. The 2010 drug strategy places an emphasis on early intervention for 
those young people and families who are at increased risk of 
developing substance misuse problems, in particular Those who are 
truanting or excluded from school, looked after children, young 
offenders and those at risk of involvement in crime and anti-social 
behaviour, those with mental ill health, or those whose parents 
misuse drugs or alcohol - need targeted support to prevent drug or 
alcohol misuse or early intervention when problems first arise. 
 
Evidence indicates that family focussed early interventions to 
strengthen functionality and parenting skills, and targeted support 
for young people in these circumstances will reduce the risks of the 
development of a range of problems including offending and 
substance misuse (Kendall, S., Rodger, J. and Palmer, H (2010).  
 
Consideration of NPS information, education and interventions to prevent 
use in the context of this prevention work is recommended. 
 
9.8. Targeted prevention interventions are also recommended for those 
who have begun to use – to deter use and prevent use being 
harmful or developing into dependence. This may include 
interventions specifically for certain groups of users such as 
clubbers and could include:  
 
 tailored information (particularly on the risks of poly-drug 
and alcohol use and injecting `unknown substances‟); 
website based information and advice;  
 brief interventions to reduce or stop use (such as those 
provided for stimulant use and alcohol misuse);  
 Localised on-site advice and help at festivals, clubs at 
other environments with a high likelihood of use - with 
staff trained in substance misuse  
 referral pathways in each local area to young people and 
young adults and other substance misuse services.  
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These prevention initiatives will require `upskilling‟ of those in contact with 
new NPS users in NPS information, advice, emerging prevention, brief 
interventions and referral for treatment for those that need it. This may 
include la range of local young people and young adult services and young 
peoples substance misuse services. 
` 
Prevention and the drug using environment 
9.9. As with other types of substance misuse the design and staffing of 
environments where supply or use is occurring can prevent use and 
reduce risk of harm associated with use (Brennan I., Moore S.C., 
Byrne E. et al). The application of this principle to NPS should be 
explored, particularly in relation to: 
 
 club and festival site environments. Interventions could 
include: regular checks of toilet and `chill-out‟ facilities to 
minimise acute toxicity cases being left unattended; areas 
designed and lit to minimise use and maximise identification 
of individuals in need of help, toilets designed without flat 
surfaces that can be used to prepare drugs, staff trained in 
identifying use acting appropriately, staff trained in basic 
substance misuse identification, effects and resuscitation 
techniques etc. 
 
 `Head shops‟: where legal substances are sold. Liaison is 
recommended with local drug and alcohol partnerships and 
shop owners and staff. These outlets may be an outlet for 
information, targeted prevention and even drug testing of 
supplies or samples.        
 
Treatment 
9.10. The treatment of acute toxicity is discussed in previous chapters. 
However, there is an emerging need to provide treatment for chronic 
NPS use and dependence. All local areas in England have young 
people‟s substance misuse services and a network of adult 
substance misuse services. The ACMD have heard evidence that 
services (including substance misuse services and sexual health 
services) are beginning to see NPS users. In addition to advice and 
information, these services can provide generic brief interventions 
and care planned support for substance misusers.  
 
9.11. In response to emerging needs, several substance misuse services 
– specialising in treatment for NPS users with serious problems or 
dependence have been developed. Some of these services are 
seeing populations who do not identify themselves as requiring 
traditional ‟drug treatment‟ and who state they would not attend 
conventional drug services. Most are self referrals, but some have 
been referred from club drug help lines or through liaison with local 
sexual health services, services for lesbian, gay, transgendered and 
bisexual people, GP‟s or accident and emergency departments. 
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9.12. Treatment protocols are being developed by these services 
including: specialist assessments; detoxification (in-patient and 
outpatient for substances including GHB/GBL); psychological and 
psychosocial treatment including cognitive behavioural therapy 
(CBT) and referral and support for drug-related health issues e.g. 
kidney and bladder problems for ketamine users. GHB/GBL 
withdrawal can result in severe and potentially life threatening 
symptoms. The club drug clinic in West London has been working 
with the Clinical Toxicology Service at Guy‟s and St Thomas‟ NHS 
Foundation Trust to develop in-patient and out-patient referral 
pathways and optimise the management of this group of patients 
 
9.13. However, there is clearly a need to share current practice, evaluate 
new treatment interventions and research `what works‟ in treating 
NPS. This may require investment by commissioners and health 
research bodies to enable us to collectively build evidence-based 
practice and disseminate this.    
 
9.14. There is also a need to specifically look for evidence of NPS use in 
local area needs assessment to inform the planning of local 
substance misuse education, prevention and treatment systems.    
 
Building knowledge and evidence-based practice in demand 
reduction 
 
9.15. A range of professionals will need to develop some basic 
competence in being able to provide NPS information and 
education, identify NPS-related problems and intervene or refer 
people for help. Core professionals requiring competence may 
include: young people and adults‟ substance misuse services, youth 
workers, sexual health services, and those delivering substance 
misuse education and prevention initiatives.   
 
9.16. Building basic knowledge and competence in preventing harm from 
NPS is challenging due the pace of change of emerging NPS use. 
This may require implementation of initiatives to create an evidence-
based knowledge base and share this knowledge with those 
responsible for training of core sets of professionals.  
 
9.17. The ACMD recommend building on local and European initiatives 
that are emerging and show promise which the UK can learn from 
and collaborate with, for example ReDNet. 
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10. Current and future legislation  
 
10.1. The primary vehicle for regulating harmful NPS is through the 
Misuse of Drugs Act 1971 (MDA). In controlling a substance under 
the Act there is a requirement for the ACMD to conduct a review of 
the evidence of harms. In addition, the ACMD will consider any 
application of a generic scope definition to cover harmful close 
analogues, although this may need updating as appropriate (see 
paragraph 7.2)  
 
10.2. The coalition set out in its agreement that: 
 
We will introduce a system of temporary bans on new „legal highs‟ while 
health issues are considered by independent experts. We will not 
permanently ban a substance without receiving full advice from the 
Advisory Council on the Misuse of Drugs‟. 
 
10.3. The Government proposed a system of Temporary Class Drug 
Orders (TCDO) in 2010 as part of the Police Reform and Social 
Responsibility Bill. The Bill has received Royal Assent and is 
available 
at:http://www.legislation.gov.uk/ukpga/2011/13/pdfs/ukpga_2011001
3_en.pdf  
 
10.4. The primary reason for having the new drug orders is one of 
responsiveness. The Government considered that the time taken to 
ordinarily control a given drug was not commensurate with the 
rapidity with which NPS have been seen to come onto the market 
and become part of users‟ repertoires. 
 
10.5. The ACMD is supportive of these proposals. Overall the ACMD 
consider that the Drug Orders should be used sparingly and 
appropriately – they should not be a substitute for consideration of 
full control under the Misuse of Drugs Act 1971, but rather a 
proportionate mechanism with which to prevent harms of a drug 
where a swift response is essential. 
 
10.6. The ACMD has been consulted during the development of the Bill, 
on the drugs clauses, and considers that it represents a positive 
legislative tool in reducing harms and also is committed to evidence- 
based policy making by maintaining, as with the Misuse of Drugs 
Act 1971, statutory consultation with the ACMD. 
 
10.7. Critical to the successful implementation of a Drug Order will be the 
flow of evidence. In invoking an order, which will be done in a 
relatively short space of time, it will be important that the ACMD has 
access to that evidence which underpins the issue and that the 
evidence is appropriate and relevant to the consideration so that it 
may make an evidenced based and robust decision.  Such evidence 
will include data from the Government‟s Forensic Early Warning 
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System (FEWS) and Drugs Early Warning System (DEWS). It is 
also critically important that resources be available to provide 
reference standards and to undertake risk analysis of NPS, 
including collecting data on the acute harm (toxicity) related to use 
of the NPS and where necessary, pharmacology studies to 
determine the activity of the NPS. 
 
International Perspective 
10.8. International bodies also consider whether substances should be 
controlled or not. For instance there are United Nations conventions 
covering narcotics and psychotropic drugs, and the World Health 
Organisation undertakes formal risk-assessments. The Council of 
Europe on 2 December 2010, following a formal risk assessment by 
the EMCDDA and Europol (EMCDDA & Europol, 2010), adopted a 
Decision submitting mephedrone to control measures (Council of 
Europe, 2010). Council of Europe. (2010). Council Decision 
2010/759/EU on submitting 4-methylmethcathinone (mephedrone) 
to control measures. 2 December 2010. Strasbourg. Available at: 
http://www.emcdda.europa.eu/attachements.cfm/att_121058_EN_C
ouncil_Decision_2010_759_EU_2December_2010.pdf and 
EMCDDA. (2010). Risk-assessment report of a new psychoactive 
substance: 4-methylmethcathinone (mephedrone). Lisbon: 
European Monitoring Centre on drugs and Drug Addiction. Available 
at:http://www.emcdda.europa.eu/attachements.cfm/att_116485_EN
_Risk%20Assessment%20Report%20on%20mephedrone.pdf 
 
10.9. However, the EMCDDA risk assessment reports, although detailed 
and thorough inevitably take considerable time to prepare – 12 
months or more. The advice on mephedrone, for example, was 
limited to one substance and appeared some 9 months after the 
ACMD recommendation on this and other cathinones. 
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11. Analogue Legislation – legal and chemical aspects  
 
11.1. Analogue legislation, in simple terms makes analogues of existing 
controlled substances automatically illegal. Analogues are defined 
as substances that bear a chemical and pharmacological similarity 
to existing controlled substances. 
 
11.2. Many English speaking countries have „analogue legislation‟ to keep 
up to date with the continually changing chemistry of new drugs. 
 
11.3. The simplest and most litigated legislation is in force in the USA. 
Stripped of its legal language, the U.S. Federal Analogue Act 1986 
outlaws a drug („B‟) if it is substantially similar to the chemical 
structure of a controlled drug („A‟) and either „B‟ has a substantially 
similar psychoactive effect as „A‟, or is intended to do so or is 
represented to do so. 
 
Advantages 
11.4. Chemically, the US Analogue Act does have some advantages over 
the incremental generic approach to the classification of controlled 
substances. Many of the chemotypes of common drugs of abuse 
are well described and delineated, and in some cases it is very easy 
to see that novel psychoactive substances have close similar 
structure to an existing and controlled drug of abuse.  
 
11.5. A recent presentation to the ACMD by the US Department of Justice 
and the Drug Enforcement Agency gave a number of examples 
where the Act was employed to control substances such as the 
simple phenethylamine 2-CT-7 which is structurally similar to 2-C-
B.The similarity is due 
to replacement of the 
bromine atom on the 
aryl ring with a thio-
propyl group (U.S. v. 
Niemoeller (Indiana 
2003)).Other 
examples include simple tryptamine analogues. These compounds 
are psychoactive and are commonly found in nature in plants, fungi, 
microbes and amphibia and they are abused due to stimulant and 
hallucinogenic properties. Examples which are covered by the 
Federal Analogue Act 
include 
dimethyltryptamine 
(DMT) and its analogue 
5-methoxytryptamine (5-
MeO-DMT) and the clear 
structural similarity of 
these compounds; even 
to non-chemists is readily obvious (they are both available on 
Wikipedia). 
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11.6. The same parallels can be drawn with reference to some of the 
newer NPS which are currently being sold through the internet. 
These include ketamine derivatives such as methoxetamine. 
 
11.7. Ketamine is a Class C drug under the Misuse of Drugs Act 1971 
and has use as an anaesthetic (Morgan and Curran 2011) whereas 
the legal high methoxetamine 
possesses a different substituent 
on the nitrogen atom and aryl ring 
to those of ketamine. At the 
present time, nothing is known on 
the pharmacology and toxicology 
of this compound. Methoxetamine 
is outside of the Misuse of Drugs Act 1971 but could arguably be 
controlled by an analogue legislation approach or by the Medicines 
Act 1968. Other striking and obvious examples where this approach 
could find utility include the new phencyclidine (PCP) NPS 
analogues which are appearing as NPS on the internet (3- and 4-
methoxy-PCP) which are highly structurally similar to PCP (“Angel 
Dust”), which like ketamine is also a dissociative anaesthetic and 
abused (McCarron et al., 1981). At the present time, little is known 
on the pharmacology or toxicology of this compound. However, 
there have been 3 recent analytically confirmed cases of acute 
methoxetamine toxicity in which the individuals presented with some 
features in keeping with Ketamine toxicity, but with more 
predominant stimulant effects than would be expected from 
Ketamine (Personal Communication: Dr Paul Dargan and Dr David 
Wood, Guy‟s and St Thomas‟ NHS Foundation Trust). 
 
11.8. This highlights a general problem of the analogue approach. It is 
highly amenable to 
certain classes of drugs 
of abuse such as the 
phenylethylamines, 
including simple 
cathinones and 
amphetamines such as 
methylone and MDMA (“Ecstasy”), where similarity is readily 
apparent.  
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11.9. Similarly while it is easy to see that the novel psychoactive 
substances 4-fluorotropacocaine is structurally related to cocaine, 
the widely available „legal high‟ dimethocaine (laroacine) appears to 
be very different.  
 
 
One chemist may argue that dimethocaine is highly similar as it 
contains an ester group and has a nitrogen atom that is substituted 
with alkyl groups just as is found in cocaine and that the distance of 
the nitrogen group to the ester group is also similar. However, 
another chemist may argue that dimethocaine is substantially 
dissimilar and the overall structural relationship between cocaine 
and dimethocaine is not apparent or obvious. Within the analogue 
Act, the onus is upon the Prosecution to demonstrate this similarity. 
If chemists can find disagreement upon structural similarity, then a 
jury is unlikely to be convinced in this specific case. Dimethocaine is 
indeed structurally related to cocaine, which was the basis for this 
class of anaesthetic (Wolverton et al., 1983). 
 
11.10. What is attractive about the analogue approach is that simple 
modifications can readily be covered. A good example of this is the 
recent formal report by Dr Les King to the EMCDDA of two 
cathinone derivatives, 2 benzylamino-1-(3,4-
methylenedioxyphenyl)propan-1-one (BMDP) and 2 benzylamino-1-
(3,4-methylenedioxyphenyl)butan-1-one (BMDB), both of which fall 
outside of the generic classification of cathinones but are clearly 
analogues of cathinones like methylone. 
 
11.11. Perhaps a hybrid approach could be adopted where certain classes 
of compound would be covered by an Analogue Act and others by 
the more incremental generic approach. 
 
11.12. From a chemical perspective, there are problems with the 
interpretation of “substantially similar structure” in the US definition 
of a chemical analogue, as it implies some qualitative measure of 
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similarity (Shulgin, 1997).  In chemistry, the term analogue is often 
used in a different context with a much wider meaning.  Chemists 
also use terms like „structurally related‟ for two compounds that 
share the same substructure (i.e. parts of the two structures share 
the same carbon skeleton), regardless of modifications to functional 
groups or heteroatoms (i.e. non-carbon atoms).  Thus when 
comparing two structures, the qualitative aspect is much less 
important to chemists and therefore it is likely that there will be a 
wide range of interpretations of the term “substantially similar 
structure”.    
 
11.13 An example is a decision by a district court (USA v. Damon S. 
Forbes et al. (Colorado 1992)) where it was decided that α-
ethyltryptamine (AET), which is not controlled in the UK, was not an 
analogue of N,N-dimethyltryptamine (DMT) or N,N-diethyltryptamine 
(DET).  These compounds are all structurally related in that they all 
have a tryptamine substructure and most chemists would regard 
them as analogues in a chemistry context.  The grounds for the 
decision were based on the fact that, 
(i) AET was a primary amine whilst DMT and DET are 
tertiary amines, 
(ii) AET cannot be synthesised from DMT or DET, and 
(iii) the effects of AET are not substantially similar to those 
of DMT and DET. 
 
 
11.14  Apart from the problems of the definition of chemical analogues, 
Analogue legislation, as exemplified by the US Federal Analogue 
Act (1986), has other potential drawbacks that have to be weighed 
against the potential benefits of this type of legislation.  With 
analogue legislation the prosecution would rely on expert opinion 
from at least two expert witnesses, a chemist and a pharmacologist. 
Likewise the defence would call their own experts. This could lead 
to a “battle between experts” under the constraints of the adversarial 
system where open discussion is not possible. It could be argued 
that transferring the responsibility to a few individual experts is less 
equitable than the current system which uses the wide range of 
expertise in ACMD. The judicial process would be costly and take 
up valuable court resources. 
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11.15  The very purpose of analogue legislation necessitates some 
elasticity and prevents a specific definition of a chemical analogue.  
However, in the United States the scope of the legislation has 
become more restricted as interpretative case law has developed. 
Eventually the analogue legislation may be no better than a carefully 
considered generic definition.  This is typified by the examples from 
US case law where 2-CT-7 was deemed to be an analogue of 2-C-B 
“Nexus” and 5-MeO-dimethyltryptamine was deemed to be an 
analogue of dimethyltryptamine. In both cases the modifications 
were foreseeable and were included within the scope of the generic 
definitions in the Misuse of Drugs Act 1971. 
 
Suggested Approach 
 
11.16 Despite these potential problems, on balance ACMD believes that 
there are positive features of analogue legislation and strongly 
recommends that serious consideration be given to an analogue 
approach to the regulation of NPS.   
 
11.17 One approach to analogue definition would be to delegate the 
authority for the determination of what qualifies as a controlled 
substance analogue to a statutory body.  In effect this is a part of 
what the ACMD already does when assessing new substances with 
reference to and by analogy to existing controlled substances and 
advising ministers on which substances merit control. In this sense 
ACMD have operated their own form of analogue legislation, e.g. 
GBL; synthetic cannabinoids; benzyl piperazine; cathinones; and 
desoxypipradrol. However, implementation of the ACMD 
recommendations is subject to the legal processes and cannot be 
fast tracked to deal with every new controlled drug analogue. 
 
11.18 When a new NPS appears on the market, it is proposed that the 
statutory body would consider the available evidence and decide 
whether the drug is an analogue of a controlled drug and if so the 
drug would then become a controlled drug using a fast track system 
similar to the temporary class drug order but without the need for a 
full risk assessment after one year.  
 
11.19 The proposed temporary class drug orders would then only need to 
be used for new „legal highs‟ that are not considered by the statutory 
body to be analogues of controlled drugs.  
 
11.20 It is notable that in Poland, which has one of the highest rates of 
NPS use in Europe, new legislation has been developed to allow 
analogues of controlled substances to be banned rapidly, using 
pharmacological similarity to controlled substance as an important 
criterion.(ReDNET News August 2011) 
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12 Conclusions and Recommendations  
 
12.1 The following recommendations are high level issues that the ACMD 
consider should be addressed by relevant Government Departments 
at strategic levels and be embedded within long term policy.  The 
ACMD understands that the issue of NPS (legal highs) is one that 
cuts across a number of Government Departments; therefore it is 
crucial that it is addressed by the Home Office with other 
Departments in equal measure. The ACMD believes that this issue 
requires a multi-faceted approach as new „NPS continue to replace 
substances that are controlled.  
 
Recommendation 1 and 2 
12.2 The issue of NPS requires a cross boundary cohesiveness to ensure 
that markets are interrupted, supply side activities interdicted and new 
compounds identified early. Spreading the net of knowledge as wide 
as possible will be crucial in addressing this issue.   
 
12.3 Recommendation: The UK should be pro-active in developing EU 
and international networks to address the issue of NPS.  
 
12.4 Recommendation: Further, steps should be taken at EU level to 
encourage source countries to halt the manufacture of such 
substances.  
 
Recommendation 3 
12.5 This report demonstrates the fast pace of change in the field of NPS. 
Many new drugs are variations around central chemical backbones. 
The ACMD has previously recommended generic controls for drugs 
such as the synthetic cathinones. However, such generic definitions 
do not often cover all compounds, nor are they intended to.  
 
12.6 Whilst it is the aim of the ACMD to ensure that those drugs that are 
harmful, with the potential for misuse, are covered by a generic 
definition, there will be those drugs that fall outside of it.  
 
12.7 The ACMD fully recognise the importance of parliamentary process 
and its scrutiny in considering legislative changes for controlling new 
drugs. The ACMD are cognisant of the Lord‟s consideration of using 
the affirmative legislation procedure for strategy instruments laid for 
new drugs. This is a more stringent procedure than the negative 
resolution.  
 
12.8 The ACMD are content with process whereby the ACMD provide 
recommendations to revisit and amend previous generic controls to 
previous NPS‟s.  
 
12.9 However, where minor adjustments to the Act are required, to update 
it in-line with analogues of all closely related substances, the 
procedure as above is still required. An example of this was 
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naphyrone which was not covered by the original cathinone generic 
as it was deemed to be sufficiently chemically different, and would not 
have fitted well within the original cathinone generic (the ACMD 
produced a new report and a generic description on this substance 
three months after the original generic description).  
 
12.10 In such cases, it would be expedient to have a process for updating 
the Act that was of minimal burden for Departmental and 
Parliamentary administration. 
 
12.11 This issue is distinct from the process by which given drugs are 
classified e.g. the proposed Temporary Class Drug Order process or 
directly via the Misuse of Drugs Act.  
 
12.12 Recommendation: For the Government to consider how to 
expedite the process of updating the Misuse of Drugs Act 1971 
where more minor amendments to generic definitions are 
required e.g. cathinones, synthetic cannabinoids, tryptamines, 
phenethylamines and ketamine derivatives.  
 
12.13 Lead Government Department: Home Office  
 
Recommendation 4 
12.14 Many „NPS are mis-sold, being products that contain illegal 
compounds. The ACMD consider that the Misuse of Drugs Act should 
be brought to bear fully on those who are intent on supplying illegal 
drugs. 
 
12.15 There is therefore a continual need to horizon scan and develop 
capability to ensure that enforcement agencies can fully discharge 
their duties under the Act.   
 
Recommendation: The application of the Act would be aided by 
continued capability developments in the area of chemical standards, 
analytical capability and forensic detection of compounds.  
 
12.16 Lead Department: Home Office 
 
Recommendation 5 
12.17 This report considered models of analogue legislation used in other 
countries to counter novel psychoactive substances that chemically 
and pharmacologically mimic controlled substances. The ACMD 
understands that similar legislation is in force in Australia and New 
Zealand. In particular the report focuses on the US Federal Analogue 
Act (1986) which is set out to address new substances that are 
similar in composition to controlled drugs.  The ACMD believes this 
approach has its merits and can be used to counter the prevalence of 
novel psychoactive substances.  
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12.18 Recommendation: Explore the possibility of new legislation 
similar to the Analogue Act (1986) used in the USA and similar 
laws in other countries, in conjunction with generic definitions 
of chemical scope.   
 
12.19 Lead Government Department: Home Office  
 
Recommendation 6 
12.20 Some NPS are analogues of licensed medicines, for example 
methoxetamine, an analogue of the anaesthetic drug ketamine, and 
methyl phenidate, an analogue of the Attention Deficit Hyperactivity 
Disorder (ADHD) medication (Ritalin).  
 
12.21 The ACMD understands that the legislation administered by the 
MHRA (Medicines Act 1968) is now mainly based on the European 
Pharmaceutical Directive. The ACMD believes that more can be 
done by the MHRA to utilise the European Pharmaceutical Directive 
to prosecute the sale of unlicensed analogues of medicines which 
are NPS‟s, even where the labelling states „not for human 
consumption‟ in cases where it is clear that the substance is in fact 
sold for human use.  
 
12.22 Many NPS are sold as „plant food‟. It is clear that the vendors use the 
legislation as shelter when the intended purpose of the products is 
plainly clear. The ACMD does not believe such thin veneers of 
legitimacy should be an impediment to the legislative system and be 
accepted when the health of individuals is at risk.  
 
12.23 Recommendation: The powers available to the MHRA in the 
European Pharmaceutical Directive (Medicines Act 1968) should 
be fully utilised to prosecute the sale of NPS. The burden of 
proof should be placed upon the supplier to establish beyond 
reasonable doubt that the product being sold is not for human 
consumption and is safe for its intended use. 
 
12.24 Lead Government Department: Department of Health and the 
Medicines Healthcare Products Regulatory Agency (MHRA).   
 
Recommendation 7 
12.25 The ACMD believes that more can be done to counter the prevalence 
of NPS by utilising civil penalties, under the jurisdiction of the 
Department of Business, Innovation and Skills, e.g. consumer 
protection legislation, especially in those cases where misleading 
statements are made about any given NPS.  Further the ACMD 
believes that there is a role here for the Trading Standards Institute to 
play, in relation to policing „head shops‟ that sell NPS („legal highs‟) 
with misleading statements.  
 
12.26 Recommendation:  The powers available in the Consumer 
Protection from Unfair Trading Regulations (2008) (CPRs) and 
 45 
General Product Safety Regulations (2005) (GPSRs) should be 
fully utilised to control the trade in NPS. If the Regulations are 
considered lacking in this respect, then thought should be given 
to amendments so that the legislation can be brought to bear.   
 
12.27 Lead Government Department: Business, Innovation and Skills   
 
Recommendation 8 
12.28 This report identifies the lack of substantive research in the area of 
novel psychoactive substances, which is crucial in making any 
informed decisions in relation to the status of any novel psychoactive 
substance.  The ACMD appreciates this has been in part due to the 
speed at which NPS have surfaced in the UK and also due to the 
lack of funds for research at the present time.  However, to ensure 
that the best possible advice is provided, concerted efforts need to be 
made to build on the research pool.    
 
12.29 We applaud the Forensic Early Warning System developed by the 
Centre for Applied Science and Technology (CAST) which analyses 
test purchases of NPS, this builds on work done by academic units 
during 2009 and 2010 (Davies et al., 2010; Ramsey et al.,2010; 
Brandt  et al, 2010a,b,c. Dargan et al 2010: Dargan PI, Hudson S, 
Ramsey J, Wood DM, The impact of changes in UK classification of 
the synthetic cannabinoid receptor agonists in „Spice‟ International 
Journal of Drug Policy 2011;22:274-277). We encourage that funds 
are available through research councils for academic units to 
continue this activity.  In addition there is an urgent need for provision 
of pure samples and reference materials of the various NPS for 
forensic science service providers to ensure accurate and reliable 
results for the analysis of both test purchase NPS samples and also 
biological samples from individuals presenting with acute toxicity 
related to the use of NPS.   
 
12.30 So far there is limited provision for biochemical or pharmacological 
research on NPS‟s. This is important as it would provide rapid 
evidence of the profile of these substances in relation to existing 
psychoactive drugs and could therefore be used to predict the 
potential for harm associated with their use. The collaboration 
initiated with the National Institute of Mental Health Psychoactive 
Drug Screening Programme in the USA will help partly to fill this gap, 
but more biological/pharmacological, and social research is urgently 
needed, and could be achieved quickly and at relatively low cost. 
 
12.31 Data collection on analytically confirmed cases of acute harm 
(toxicity) presenting to hospitals associated with the use of NPS is 
essential for informing decisions on the classification of these 
substances. Information on acute harm is currently collected on an 
ad hoc basis by a few specialist units in the UK and this has provided 
data from recent ACMD considerations of mephedrone and the 
cathinones, „spice‟, GBL/1,4-BD, 1-BZP and other compounds. It is 
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important that resources are made available to increase data capture 
in this important area to enable ACMD and the government to be 
able to make decisions based on the actual harms associated with 
NPS. 
 
12.32 Recommendation: Provide resources for research on the 
chemistry, pharmacology, acute harm (toxicity) and social 
harms of novel psychoactive substances and encourage 
Business Innovation and Skills Department (BIS) and all 
research councils to put out calls in these areas.   
 
12.33 Lead Government Department: Home Office/Business, Innovation 
and Skills   
 
Recommendation 9 
12.34 The ACMD understands that the main method of promoting NPS is 
via the internet, where more often than not misleading claims are 
made about the substance, e.g. purporting that substances are bath 
salts or fish food.  These terms are clearly used to legitimise the 
substances.   
 
12.35 Recommendation: Request the Advertising Standards Authority 
(ASA) to investigate claims made by NPS websites.  
 
12.36 Lead Government Department: Home Office 
 
12.37 Recommendation: That a national system be implemented (by 
Trading or Local Authority Licensing) whereby all suppliers and 
potential suppliers or novel psychoactive substances are warned (by 
way of an official notice) that substances they sell may contain 
controlled substances.  This will then put the onus on them as 
suppliers to ensure none of their products contain controlled 
substances.    
 
Recommendation 11 
12.38 The ACMD believes that education and awareness of NPS and 
associated skills development is crucial in relaying the message that 
although a substance may be legal it does not mean it is safe.  Whilst 
providing information on potential harms of NPS is important and 
should be included within school-based drug awareness 
programmes, the changing nature of the NPS market means that 
developing health literacy and supporting healthy decision making 
around substances in general is also a useful long term goal. PSHE 
(Physical, Social and Health Education) provides an excellent 
framework for the delivery for such activities, and the findings of the 
current review of PSHE education should, in accordance with Ofsted 
recommendations, be used to promote consistency across schools in 
the provision of high quality, evidence-based substance use 
education.  
 
 47 
12.39 The ACMD recommend building on local and European initiatives 
that are emerging, for example ReDNet. 
 
12.40 The ACMD recommends that the government raise public awareness 
around NPS and implements strategies to reduce the demand for 
NPS by including NPS in substance misuse education in schools; 
developing targeted prevention initiatives and also treatment for 
those with acute problems (eg within A&E) and dependency. The 
following tools should be utilised to counter the prevalence of NPS;  
 
1       Training  
 
Training on NPS should be provided to young people and other services – 
both specialist and generic services Specialist substance misuse services 
 
2              Monitoring 
 
Better monitoring of NPS needs to be developed to ensure that new drugs 
and trends of use are identified as early as possible (see paragraph 12.22). 
 
3              Information and advice for NPS users 
 
Credible sources of information and advice need to be developed for 
young people taking NPS. 
 
4              Wider public information 
 
Care should be undertaken with the wider reporting and dissemination of 
information on NPS so as not inadvertently to encourage wider 
experimentation and use particularly among the under 16s. Education on 
the harms associated with NPS should specifically be delivered to young 
children in the latter stages of primary education so that they can be made 
aware that NPSs are highly likely to carry the same harms as controlled 
drugs of abuse. 
 
12.41 Lead Government Department: Department for Education 
 
Recommendation 12 
 
12.42 There is clearly a need to share current practice, evaluate new 
treatment interventions and research `what works‟ in treating NPS 
dependence.  
 
12.43 Recommendation: That there should be investment by 
commissioners and health research bodies to enable them to 
collectively build evidence-based practice and disseminate this. 
 
12.44 Lead Government Department: Department of Health  
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Recommendation 13 
 
12.45 The ACMD recommends that demand reduction strategies 
should be developed including education, prevention and 
treatment interventions: 
 
- develop credible evidence-based public health messages on NPS to 
allow potential users to understand harms potential associated with 
NPS the choices they are making 
- include NPS drug education in schools and targeting parents and 
ensure those delivering drugs education have current knowledge of 
NPS 
- local areas develop evidence-based targeted prevention 
interventions for potential and new NPS users 
- based on local needs assessments, develop treatment interventions 
to tackle acute NPS toxicity and NPS misuse and dependence, 
particularly develop competence in A&E services and young people 
and adult substance misuse services. 
 
This requires national co-ordinated NPS knowledge and competency 
projects to keep abreast of emerging NPS and what are effective 
interventions – to inform public health messages, training and spread 
best practice in interventions.   
 
12.46 Lead Government Department: Department of Health  
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Annex A 
An overview of the pharmacology of NPS 
 
Cocaine or Amphetamine-like drugs 
Many controlled drugs, although there may be chemical diversity, 
share a common mechanism of action in that they increase levels of brain 
monoamine chemical messengers by blocking their re-uptake after 
synaptic release. The monoamines involved are serotonin, nor-adrenaline 
and dopamine. The relative contributions of the individual monoamines to 
the stimulant/euphoric effects vary depending on the particular class of 
drug. All such drugs, to a varying degree, have additional actions, some of 
which may, especially at high doses, be manifested as adverse or toxic 
effects.  
 
Controlled drugs possessing this mechanism of action include 
amphetamine, methylamphetamine, ecstasy (MDMA), and cocaine. 
Mephedrone and naphyrone (also known as NRG-1) which are 
amphetamine-like in their pharmacology and chemistry and which were 
widely advertised and used as legal highs, have now been added to the list 
of controlled drugs. Benzylpiperazine (BZP) with a mechanism of action 
more akin to that of MDMA is now banned in most countries. More recently 
desoxypipradrol, also a material with amphetamine-like effects was found 
to be the active principle in some samples of „Ivory Wave‟, and has been 
made the subject of an import ban and control under the Misuse of Drugs 
Act 1971.  
 
 
 
 
 
                
 
There are still other amphetamine-like legal highs readily available. One 
such is MDAI (methylenedioxy-aminoindane) promoted on websites as 
being capable of releasing serotonin without the undesirable neurotoxic 
effects of MDMA or the stimulant effects of amphetamine. Data on its 
pharmacodynamics and pharmacokinetics are limited and there are only 
anecdotal reports on its effects on users.  
 
Dimethocaine (see above) is promoted on websites as a legal substitute 
for cocaine. Like cocaine, it acts as an anaesthetic, but it also inhibits the 
dopamine transporter in the brain and so reduces clearance of dopamine 
from the synaptic cleft and, from the limited information available on its 
pharmacology, it appears to be approximately equipotent with cocaine. But 
as yet it appears not to be widely used 
 
LSD like drugs 
Numerous tryptamine derivatives have been shown to have similar 
pharmacological actions as LSD-25. Two materials, alpha-
methyltryptamine (AMT) and 5-methoxydiallyltryptamine (5-MeO-DALT) 
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are becoming more widely publicised by websites selling NPS. Both are 
currently outside the UK‟s generic controls on tryptamines and are 
therefore legally available. However, there is considerable overlap between 
the pharmacology of agents in this group and amphetamine-like drugs 
such that if members of this class of drugs had an action at certain 
serotonin receptors their pharmacology will then be LSD like. It is also 
possible to find agents that have a mixture of monoamine releasing and 
serotonin-receptor ligand activity.  
 
Phencyclidine (PCP) and ketamine-like agents 
Phencyclidine and ketamine were both initially developed as anaesthetic 
agents for human use but the use of phencyclidine was discontinued 
because of unacceptable side effects including hallucinations and 
psychotic reactions.  However, ketamine is still used in paediatric care. 
Both continue to be used as veterinary anaesthetics. Both compounds 
have emerged as street drugs producing florid behavioural effects with a 
high incidence of „bad trips‟. The predominant pharmacological action is 
antagonist activity at central NMDA/glutamate receptors. 
 
Both drugs are now controlled substances, as are some of the analogues 
of PCP, but other analogues including methoxetamine (a close analogue of 
ketamine) and the 3- and 4-methoxy derivatives of PCP are publicised on 
websites as legally available analogues. No information regarding their 
pharmacology or biochemistry is available but it would be surprising if they 
did not share the same activities and therefore have a potential to produce 
the same psychoactive effects as the parent compounds.  
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Annex B 
Background – NPS in an Historical Context 
This section illustrates in more detail some of the substances that have 
been used legally as intoxicants for many years, and reviews some of the 
more recent examples which have been reviewed by ACMD in the past few 
years.  Alcohol, tobacco and caffeine are among the most widely used 
psychoactive drugs, but they do not form part of this review – which is 
focussed on substances which are controlled, or likely to be controlled 
under the Misuse of Drugs Act 1971 
 
Nitrous Oxide 
One of the earliest examples is nitrous oxide (N2O), a colourless sweet-
tasting gas, often referred to as “laughing gas” because of the sense of 
hilarity it may induce in users (Sheldin et al, 1993). First discovered by 
Joseph Priestley in 1772, its use was popularised by Humphrey Davy who 
inhaled the gas and reported its pain relieving and euphoric effects in 
1784. Later the gas came into medical use as a useful anaesthetic for 
dental operations and other uses such as in childbirth where its short 
duration of action was an advantage (Becker and Rosenberg, 2008). 
Among the British upper classes “laughing gas parties” became popular in 
Victorian times; such parties also took place in the USA.  Nitrous oxide still 
has widespread legitimate medical, dental and veterinary uses and has 
also found applications as a component of rocket fuel; a fuel additive; an 
aerosol dispersant; and in the catering industry in the dispensing of 
whipped cream. This latter use forms the basis for its legal sale by many 
web sites, in the form of small canisters or larger tanks, labelled for 
catering use – although clearly intended for recreational use.  When 
inhaled the gas induces a brief period of euphoria which may be 
accompanied by “tears of joy”. Users often wish to repeat their positive 
experiences with the gas, although there is no firm evidence of physical 
dependence.  It appears to have few if any short term adverse effects, 
other than mild headache for some.  Long term abuse can cause 
peripheral sensory neuropathies.  Deaths linked to nitrous oxide are due to 
hypoxia replacement of oxygen with nitrous oxide (some of the deaths 
have also involved use of N2O in an enclosed space which exacerbates 
hypoxia and/or in bags).  
 
The recreational use of nitrous oxide has seen a sudden revival of interest 
in the 21st century, and it is now commonly available in certain clubs and at 
music festivals – where it is purchased in the form of gas-filled balloons.  At 
the Glastonbury Festival in 2010, for example, it was reported that the 
ground was littered with discarded yellow balloons of this type.  
 
The sale of nitrous oxide for catering or other legitimate commercial use is 
entirely legal, although its sale in forms such as gas-filled balloons clearly 
intended for human use violates the Medicines Act, and could be dealt with 
by MHRA – although there have been no prosecutions at Court. Five 
offenders have been arrested at the Glastonbury Festival over the last 2 
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years for supplying it for inhalation purposes and on the advice of the 
MHRA all have received Police Cautions. 
 
Solvent abuse 
A wide range of volatile materials can cause a temporary intoxication when 
the vapours are inhaled (Spurgeon, 2006). They include petrol, propane, 
butane, acetone and many others. These are present in hundreds of 
household products freely available over the counter at relatively low cost. 
Solvent abuse thus appeals to those who cannot afford or do not have 
access to other intoxicants. Children, teenagers and marginalised adults 
have traditionally been most likely to indulge in this behaviour. Solvents are 
inhaled from a soaked rag, or directly from an open container. Because the 
solvents are inhaled into the lungs, their effects are rapid in onset giving 
the desired “rush” of intoxication and euphoria, sometimes accompanied 
by hallucinations. Volatile substance abuse can also be undertaken in 
enclosed spaces and/or by inhalation from a bag which increases the risk 
of hypoxia and therefore the risk of complications and fatalities. 
 
Repeated solvent use can have serious harmful effects, including liver and 
kidney damage, and in some cases death, usually from respiratory 
depression, inhalation of vomit, or cardiac arrhythmia. The popularity of 
solvent abuse was fuelled by its incorporation into pop culture in the 
1970‟s. Some punk musicians, for example, glorified their use of solvent 
inhalation as a way of shocking the adult population.  The growing number 
of solvent-induced deaths, particularly among children, however, led to the 
introduction of the Intoxicating Substances (Supply Act), 1985 which made 
it a criminal act to supply anyone under the age of 18 with a wide range of 
intoxicants. These include solvent-based glues, dry cleaning fluid, nail-
varnish remover, lighter fuel refills, and a host of other materials. 
Manufacturers also responded by reducing the retail package size of 
products containing intoxicant solvents. 
 
Although solvent abuse is still widespread, it has become far less 
prominent than it was 30-40 years ago, but deaths continue to occur – for 
example, there were 38 in the UK in 2008 and 46 in 2009. Volatile 
Substance associated deaths have been monitored by a programme at St 
Georges Hospital London (VSA reports).  
 
‘Poppers’ 
Poppers‟ are small bottles filled with volatile liquid chemicals called alkyl 
nitrites. Recreationally they are usually sniffed straight from the bottle, after 
breaking the sealed top, and they deliver a short, sharp high (Haverkos et 
al, 1994). Alkyl nitrites also relax smooth muscles including those 
surrounding blood vessels, thus increasing blood flow, and those around 
sphincters, thus facilitating intercourse. There are several variants in the 
alkyl nitrite group, including amyl nitrite, butyl nitrite and isobutyl nitrite. 
 
Amyl nitrite is an active ingredient in licensed medicines, mainly for the 
treatment of cyanide poisoning. This is normally in the metallurgical 
industry where cyanide is used in activities involving gold, but there are a 
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few other circumstances where the product might be required. Any 
unlicensed product containing amyl nitrite is likely to fall within the 
definition of a medicinal product and, because it is unlicensed, be in breach 
of medicines regulations and therefore can be dealt with by MHRA. It is 
very unlikely that any ‟poppers‟ on the UK market contain amyl nitrite. 
 
Isobutyl or isopropyl nitrite esters are used as the active ingredients in 
„poppers‟. Neither substance is used as an active or excipient in any 
licensed medicine.  Many varieties of colourfully packaged ‟poppers‟ are 
freely sold at music festivals and in high street „head shops‟. They are 
relatively cheap and appeal to young people looking for a short-lasting 
high. ‟Poppers‟ are normally marketed by manufacturers or importers as 
“room-odouriser”. Retailers often describe them as aromas. They are sold 
under brand names such as GOLD, RAVE, REDS and many others, 
mainly from sex shops (their effects are said to enhance sexual pleasure) 
or “head shops” selling alternative life-style products - not from home-ware 
shelves in mainstream supermarket chains. „Poppers‟ are often sold in gay 
nightclubs and also in head shops. 
 
„Poppers‟ would appear to fall within the scope of „The Intoxicating 
Substances (Supply) Act 1985‟ and, as there is evidence that „poppers‟ are 
being sold to minors in retail outlets around the country, it would seem 
sensible that they should be dealt with using this legislation.  
 
Trading Standards Departments (BIS) are responsible for the enforcement 
of the relevant legislation.  
 
‟Poppers‟ are not subject to the controls of the Misuse of Drugs Act 1971  
and there are no plans to bring them under the control of the 1971 Act as, 
at present – unlike other substances of abuse – their misuse, within the 
terms of section 1 of the Act, is not seen to be capable of having "harmful 
effects sufficient to constitute a societal problem". There have been a small 
number of deaths from their use. The ACMD is also aware that the use of 
„poppers‟ can lead to methaemoglobinaemia in users.  
Methaemoglobinaemia may cause significant tissue hypoxia, leading to 
severe, potentially life-threatening clinical features and/or death (Hunter L, 
Gordge L, Dargan P, Wood DM. Methaemoglobinaemia associated with 
the use of cocaine and volatile nitrites as recreational drugs: a review. 
British Journal of Clinical Pharmacology 2011; 72:18-26.)  
 
As sniffing isobutyl nitrite causes a physiological effect, the MCA 
(Medicines Control Agency) (as was; now Medicines and Healthcare 
products Regulatory Agency (MHRA)) brought a prosecution in 1999. This 
was on the basis that ‟Poppers‟ containing isobutyl nitrite were medicines 
and hence required a product licence for sale and supply in the UK. The 
company brought to trial (QUIETLYNN who manufactured and supplied 
these products) and its directors – were subsequently found not guilty. It is 
understood that there was sufficient argument by the defence that these 
products did not cause significant harm. An appeal was considered but not 
pursued and the status of the products has remained under review since 
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then. No further prosecutions have been attempted as there was no 
material change to the products‟ ingredients. In addition, since the court 
case, companies have been very careful to keep the description of 
products to „room odourisers‟ and this is reflected in the instructions for 
use. 
 
The introduction of The Dangerous Substances and Preparations (Safety) 
Regulations 2006 has altered the status of certain ‟poppers‟ products. The 
legislation which is enforced by the Department for Business, Innovation 
and Skills (BIS), prohibits the supply of isobutyl nitrite, as it has been 
classified as a carcinogen, As a result, the use of isobutyl nitrite in 
‟poppers‟ is effectively banned. Therefore, products manufactured and sold 
containing this substance are in breach of regulatory requirements and 
could be dealt with by Trading Standards Departments using powers 
drawn from the Consumer Protection Act 1987.  Further the ACMD are 
aware of risks associated with nitrites as they can be highly flammable with 
potential for harm related to burns if they are used by smokers. 
 
Manufacturers and distributors, however, in recognition of the ban on 
isobutyl nitrite, have substituted isopropyl nitrite as the active ingredient. It 
is likely that that this will have a similar physiological effect to isobutyl 
nitrite. This provides an early example of how small changes in the 
chemical formulae of products can be used to avoid the law. 
 
Plants and fungi 
A number of natural species contain psychoactive chemicals, and fresh or 
preserved plant and fungal materials have long been offered for sale via 
„head shops‟ and internet outlets. The legal position regarding such natural 
materials is complex, a situation which, in the early part of this century, a 
number of distributors made use of to enable them to conduct large-scale 
and overt marketing of non-native mushroom species containing 
hallucinogens (“magic mushrooms”). This activity was largely terminated 
by the Drugs Act 2005, which controlled “fungus (of any kind) which 
contains psilocin or an ester of psilocin”. However, other natural materials, 
such as Salvia divinorum and „Fly Agaric‟ mushrooms, which contain other 
psychoactive chemicals, remain on sale. 
 
Any preparations containing controlled drugs are controlled under the 
Misuse of Drugs Act 1971, and this includes  plant materials if there is 
evidence of the material being prepared 'by the hand of man' (there is a 
large amount of case law on this topic mostly relating to Psilocybe 
mushrooms prior to the Drugs Act 2005). 
 
A recent attempt to prosecute for supply of dried cacti containing 
mescaline (R v Sette, 2007) was struck down on the basis that, as 
hallucinogenic cacti weren‟t specifically addressed in the 2005 Drugs Act, 
their legal position remained too obscure to permit a prosecution to 
proceed. 
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1-Benzylpiperazine (BZP) 
1-Benzylperazine (BZP) is a synthetic drug prepared from piperazine, an 
antihelminthic medicine used to control intestinal roundworms. Piperazine 
itself has no psychoactive properties, but BZP acts as an amphetamine-
like psychostimulant. Laboratory animals are unable to distinguish the 
subjective effects of BZP from those induced by cocaine or amphetamine 
in drug discrimination tests. In recreational use the human dose of BZP is 
usually 100mg taken orally as a tablet or powder (EMCDDA Risk 
Assessment,)  
 
The recreational use of BZP first became popular in New Zealand, where 
for a period of several years from 2000 it was widely available as a legal 
“party drug”. BZP was freely available over the counter in many shops and 
sold under a variety of brand names. Manufacturers formed the “New 
Zealand Social Tonics Association” with its own code of practice to ensure 
the maintenance of quality standards. The New Zealand Government 
placed BZP into a new “Class D”, under which, like alcohol and tobacco, its 
sale was restricted to adults. This social experiment terminated in 2008, 
when the New Zealand Government made BZP illegal under their Misuse 
of Drugs Act.  
 
By the early years of this century BZP and some related chemical 
analogues, claimed to be more ecstasy-like in their profiles, became legally 
available in Europe. The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) conducted a risk assessment of BZP in 2007 and 
concluded that its sale in Europe should be controlled. In 2007 the UK 
MHRA issued a notice that the sale of BZP as a product for human use 
was illegal, and ACMD conducted its own review of the evidence and 
recommended that BZP and various derivatives should be made illegal as 
Class C substances under the MDA (ACMD:1-Benzylpiperazine Report, 
2008) – this was accepted and enacted  into law in December 2009. 
 
There seems little current interest in BZP as a product but recent Police 
seizures show that users and dealers alike are mistakenly selling and 
using BZP or the related drug trifluoromethyl-phenyl-piperazine (TFMP) in 
the belief that it is Ecstasy. Nationally, Police seize far more Piperazines 
than Ecstasy. 
 
There have been a total of 36 deaths in which BZP has been implicated, 
usually in conjunction with alcohol (National Programme on Substance 
Related Deaths [npSAD] 2011). 
 
GHB and its analogues GBL and 1,4-butanediol  
Gamma-butyrolactone (GBL) and the related substance 1,4-butanediol 
(1,4-BD) are colourless liquids widely used in the chemical industry as 
solvents or precursors for plastics manufacture. They are also present in a 
variety of domestic products as solvents, for example as nail-polish 
remover or for cleaning oily machinery. It is estimated that the UK chemical 
industry imports 1000 tons of GBL and 5000 tons of 1,4-BD annually. 
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Both substances are rapidly metabolised in the human body to form 
gamma-hydroxybutyrate (GHB). GHB acts as an intoxicant, and was 
reviewed some years ago by ACMD, culminating in a recommendation in 
2003 that it be banned under the MDA as a Class C substance. More 
recently GBL was recognised as representing a legal loophole, legally 
available but converted within a few minutes after ingestion to the banned 
substance GHB. Until recently pure GBL could be purchased from various 
internet retailers in amounts up to 10 litres. A 250 ml bottle, for example, 
could be purchased for £20. Since the human intoxicant dose is 
approximately 1ml, this was equivalent to 250 human doses, at a unit price 
of 8p. Not surprisingly, the use of GBL as a cheap intoxicant grew, 
particularly in the club scene.  GBL induces a rapid intoxication and 
euphoria, accompanied by a loss of inhibitions. Unfortunately, the dose-
response is fairly steep and somewhat higher doses can lead to sedation 
and sleep, and in overdose to coma, hypothermia and bradycardia – 
sometimes culminating in death. The npSAD has identified at least 96 
deaths in the UK since 1995 in which GBL/GHB were associated (the rapid 
metabolism of GBL makes its detection in body fluids or tissue impossible); 
at least 22 of these involved GBL (np-SAD, 2011). Although there is no 
direct evidence, GBL has been implicated in drug-assisted sexual assault, 
There is increasing evidence that the repeated use of GHB or GBL are is 
capable of inducing dependence 
 
ACMD reviewed the evidence for GBL and 1,4-BD misuse and 
recommended that both substances be brought under the MDA (ACMD 
2008 GBL & 1, 4-BD: Assessment of risk to the individual and communities 
in the UK). This advice was implemented in December 2009.  However, 
because of the important industrial and commercial uses of these 
substances exemptions had to be made for these uses and their 
classification as Class C drugs represents only a limited means of control. 
How effective the legal banning of GBL and 1,4-BD under the MDA has 
been remains to be seen. The rise in the popularity of GBL provides 
another illustration of how small changes in chemistry can yield substances 
that avoid legal bans. 
 
More than a hundred deaths have been attributed to GHB/GBL (national 
programme for substance abuse deaths 2011).  
 
Synthetic cannabinoid receptor agonists – ‘Spice’ 
In the early years of the century a novel psychoactive substance product 
was marketed by internet retail sites and high street “head shops” under 
the product name “Spice”. It was imported from China and claimed to be a 
smoking mixture composed of various herbs. The product was attractively 
packed in silver or gold foil sachets and modestly priced at £10-20. 
 
Users discovered that smoking this product had an intoxicant effect 
remarkably similar to that induced by smoking illegal cannabis, and this 
information spread rapidly through user internet sites.  The popularity of 
“Spice” was at first mysterious, since numerous other herbal products 
previously claiming to act as novel psychoactive substances had usually 
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proved disappointingly ineffective. It was a brilliant piece of analytical 
detective work by a German forensic laboratory that first revealed the truth.  
The herbal mixture in the product had been laced with small quantities of 
synthetic chemicals that acted on the cannabinoid receptor in the brain to 
simulate the actions of natural cannabis.  
 
During the 1970s, following the discovery of Δ9- tetrahydrocannabinol 
(THC) - as the principal psychoactive ingredient in herbal cannabis, the 
pharmaceutical industry generated numerous synthetic cannabis-like 
chemicals with the goal of separating the medical benefits of cannabis from 
its intoxicant actions. This venture proved unsuccessful and was 
abandoned, but detailed reports of hundreds of different synthetic 
cannabinoids remained in the scientific literature (Makriyannis and Rapaka, 
1990; Iversen, 2008a).  Thirty years later this literature was rediscovered 
and a range of different synthetic cannabinoids were synthesised to add to 
the “Spice” product.  Some of these substances are more than a hundred 
times more potent than cannabis itself, so only minute amounts had to be 
added to the herbal product – making their analytical detection extremely 
difficult. This was compounded by the use of several different synthetic 
cannabinoids in different batches of „Spice‟.  
 
The ACMD reviewed this issue and concluded that although little detailed 
information was available on the pharmacology or harmfulness of these 
compounds, they could be assumed to carry the same properties and to 
possess harmfulness commensurate with that of cannabis – which had 
been thoroughly reviewed previously. This „argument by analogy‟ was to 
prove valuable in other contexts as novel psychoactive substances 
emerged. ACMD made an  extensive  recommendation for a chemical 
generic ban covering virtually all known synthetic cannabinoids, in five 
distinct chemical classes, recommending that they be made Class B drugs 
under the MDA (ACMD Report: Consideration of the Major Cannabinoid 
Agonists, 2008). These recommendations were accepted and passed into 
law in December 2009. In light of the identifications of substances such as 
RCS-4 and AM-694 by the HO-CAST Forensic Early Warning System, it is 
clear that loopholes have already been found and these substances are 
legally available. The use of synthetic cannabinoids in this product 
illustrates the increasing sophistication of the chemists responsible, who 
mined the scientific literature to obtain information on the synthetic 
cannabinoids published by academic and pharmaceutical laboratories in 
the 1970s. Further there is published evidence that products containing 
synthetic cannabinoids remain widely available that newer synthetic 
cannabinoid receptor agonists that fall outside the legislation are also now 
available (Dargan PI, Hudson S, Ramsey J, Wood DM.  The impact of 
changes in UK classification of the synthetic cannabinoid receptor agonists 
in „Spice‟).  
 
Ecstasy 
The psychoactive effects of this substance (3,4-methylenedioxy- 
methamphetamine or MDMA) were first reported by the American chemist 
Alexander Shulgin in the 1960s. It became popular as a “party drug” in the 
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USA and later in Europe because of its unique ability to act both as an 
amphetamine-like stimulant and as an “empathogen” – causing users to 
feel socially relaxed and euphoric. MDMA was also widely used as an aid 
to psychotherapy by psychiatrists, particularly in the USA. Its use as a 
recreational drug took off as part of the “rave dance” culture in the USA 
and Europe during the 1980s, and it continues to be widely used despite 
legal bans (Iversen 2008b). 
 
In Britain MDMA was made illegal in 1977 under the Misuse of Drugs Act 
1971 – and was given a “Class A” status – which it continues to retain. 
Despite the severe penalties potentially associated with possession or 
dealing in Class A drugs, MDMA continues to be widely used. According to 
the British Crime Survey approximately 250,000 young people, aged 16-
24, and some 40,000 admit to being regular users – although in this case 
regular usually means “at weekends” rather than every day. ACMD 
undertook a detailed review of the use of MDMA and the harms associated 
with it (ACMD: MDMA (Ecstasy): A Review of its Harms and Classification 
under the Misuse of Drugs Act 1971, 2008). The review concluded that the 
medical and societal harms of MDMA were not commensurate with its 
Class A status, and recommended that it be downgraded to Class B. The 
Home Secretary, however, did not accept this recommendation.  
 
By the time ecstasy became popular in the UK in the late 1980s, it was 
already a Class A controlled drug, by virtue of the generic controls placed 
on phenethylamines in 1977 in response to the appearance of other 
psychoactive phenethylamines such as DOB (2,5-Dimethoxy-4-
bromamphetamine) and STP (2,5-Dimethoxy-4-methylamphetamine). As 
stated under BZP (para 2.16 above)  the majority of "ecstasy tablet" users 
are in fact taking BZP, but over the last 2 years there have been significant 
increases in the use of Crystal Ecstasy a much more potent form of the 
drug. 
 
In the USA MDMA was legally available until banned as a Schedule 1 drug 
in 1985. In Britain MDMA was available legally until 1977 – but curiously its 
widespread use occurred after it was made illegal.  
 
Cathinones  
(i) mephedrone 
This is also a wholly synthetic chemical, sometimes referred as the first 
“internet drug”. Mephedrone was a 'designer drug' in that it was specifically 
designed as a Novel Psychoactive Substance that had not previously been 
reported in the literature. The rapid spread of availability and use of this 
cathinone derivative psychostimulant in the UK was dramatic during the 
latter half of 2009 and in the first quarter of 2010. Mephedrone (4‟-methyl-
methcathinone)  is a chemical derivative of the naturally occurring 
amphetamine-like substance cathinone – the active ingredient in the shrub 
khat (Catha edulis).  Whereas herbal khat has not so far been a controlled 
product, cathinone has long been banned under the MDA as a Class C 
substance. It acts as a weak form of amphetamine. Mephedrone is more 
potent than cathinone and its intoxicant effects combine the stimulant 
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properties of amphetamine with the empathogenic profile of MDMA 
(EMCDDA Drug Profiles).  
 
The reported dose by users of mephedrone is around 50-100mg, usually 
taken orally, but sometimes insufflated into the nose. In rare instances it 
has been intravenously injected. The easy availability of mephedrone 
through the internet led to many young people who had never previously 
used illegal drugs to experiment with it. It is also possible that some long 
term cocaine users, disappointed by the poor quality of street cocaine, 
were attracted to a legal product which – at least  initially – lived up to the 
purity standards claimed (>98%). Use was spread rapidly through internet 
social network sites, aided also by press and television coverage. Supplies 
of kilogram amounts could be obtained fairly cheaply from internet 
suppliers (1kg for £2000 - @10-20p per human dose). Users may have 
been seduced into thinking that “it is safe because it is legal”. Typically 
during an evening out, users would dose repeatedly and use their entire 
supply of approximately 1g.  
 
Since mephedrone and related compounds were described by internet 
retailers as “plant food” or “fish food” and clearly indicated as “NOT FOR 
HUMAN CONSUMPTION” they appeared to be immune from regulation 
under Trades Description or Medicines Act legislation – although this has 
never been challenged. 
 
The ACMD first became aware of this novel psychoactive substance in 
July 2009 from seizures at a music festival on the Isle of Wight. Monitoring 
its rapid rise in use in the UK, ACMD alerted the then Home Secretary in 
December 2009 of the possible dangers of this substance, and launched a 
risk assessment.  As in the case of the synthetic cannabinoids, little 
published scientific information was available on mephedrone, so ACMD 
had to argue largely by analogy with amphetamines – on the grounds that 
the cathinones are closely related chemically and in their actions. Although 
little was known of the long-term harms caused by mephedrone, the 
harmfulness of the classical amphetamines was well documented. This 
resulted in the submission of a detailed report in March 2010 with the 
recommendation of an immediate import ban, and that mephedrone, 
together with a broad range of related cathinones derivatives, be banned 
under the MDA as Class B substances (ACMD- : Consideration of the 
Cathinones, 2010). A number of bodies such as the National Poisons 
Information Service, Guy‟s and St Thomas‟ NHS Foundation Trust and 
other clinicians/scientists provided data that demonstrated the potential for 
toxicity associated with the use of Mephedrone. There has been some 
confusion over names „Mephedrone‟, „Methadone‟ and „Methedrone‟, 
especially at the early stages of Mephedrone emergence in the UK, there 
may have been some mis-recording of Mephedrone presentations at A&Es 
where at times it was being recorded as Methadone toxicity. The acute 
toxicity was used to inform the decision made to classify it.  This 
recommendation was rapidly accepted and turned into law in April 2010 
(ACMD, 2010).  Details of the npSAd report on mephedrone associated 
deaths are provided in Section 9 below. 
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(ii)  Naphthylpyrovalerone (Naphyrone)  
Despite the broad chemical generic ban on psychoactive cathinones 
imposed in April 2010, suppliers were able to find some loopholes, and 
within days a naphthyl derivative, Naphthylpyrovalerone (commonly 
referred as NRG-1) which lay outside the generic scope was offered for 
sale by internet retailers – advertised as “the legal alternative to 
mephedrone”. ACMD considered this case urgently, arguing again by 
analogy with the known amphetamines together with some neurochemical 
properties of the substance which had been published – placing it in the 
category of cocaine/amphetamine-like substances. ACMD recommended 
that Naphthylpyrovalerone and related chemical analogues be banned 
under the MDA as Class B drugs, and this was accepted and enacted into 
law in mid-2010. (ACMD: Consideration of the naphthylpyrovalerone 
analogues and related compounds, 2010). There are at least two cases in 
which naphyrone has caused or contributed to death (np-SAD). 
 
The cathinones illustrated the speed with which Novel Psychoactive 
Substances can become available and used – and the rapidity of the 
suppliers‟ reaction to the initial ban – almost immediately finding legal 
loopholes to exploit. We must expect this to happen again on future 
occasions.  
 
Desoxypipradrol 
During 2010 a new Novel Psychoactive product „Ivory Wave‟ began to be 
advertised on internet sites and became more widely used, following the 
ban on cathinones. This time the retailers failed to disclose the active 
psychoactive ingredient(s), stating that the product should be used as 
“bath salts” and that it contained „Epsom salts, bicarbonate of soda and 
natural amino acids‟. Analysis of test purchases, however, initially revealed 
the active ingredient to be methylenedioxypyrovalerone (MPDV) – one of 
the banned cathinone derivates. Subsequent purchases, however, 
revealed a different psychoactive ingredient – desoxypipradrol. The Home 
Office Centre for Applied Science and Technology Forensic Early Warning 
System found that desoxypipradrol was also identified in a purchase from a 
head shop in Edinburgh in March 2011 under the product name „Lunar 
Wave‟.  
 
Desoxypipradrol is not controlled and is closely related chemically to the 
Class B drug methyl phenidate (®Ritalin) – an amphetamine-like 
psychostimulant used in treating Attention Deficit Hyperactivity Disorder 
(ADHD) in children. The ACMD began an investigation of this new product 
in mid-2010 and heard reports of users admitted to hospital A&E units with 
persistent severe agitation, sometimes lasting for several days, often 
accompanied by psychosis. These effects were consistent with the 
properties of desoxypipradrol, as an amphetamine-like drug. After 
consideration of the reports of the harmfulness of this new product, the 
ACMD recommended that the Home Secretary impose an immediate ban 
on the import of desoxypipradrol (under the Open General Import Licence), 
and this was promptly acted upon (ACMD, 2010). There are two cases 
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awaiting inquest in which desoxypipradrol is believed to have caused or 
contributed to death in the summer of 2010, as well as several deaths in 
which MDPV was detected (np-SAD). The ACMD undertook a further 
detailed analysis of desoxypipradrol and recommended to the Home 
Secretary that it be controlled under the Misuse of Drugs Act 1971 (ACMD, 
2011). 
 
 
 62 
 Annex C: Reporting of drug-related deaths.  
 
Established in 1997, and sponsored by the Department of Health, the 
National Programme on Substance Abuse Deaths (np-SAD) regularly 
receives notifications on a voluntary basis from coroners and other sources 
across the UK and Islands when inquests and other formal investigations 
into drug-related deaths or deaths of individuals with a history of drug use 
have been completed. This information is collated, analysed and 
disseminated in several ways: annual reports on drug-related deaths in the 
UK; contributions to the annual reports of the UK Focal Point, the 
European Monitoring Centre for Drugs and Drug Addiction, and United 
Nations; academic papers; information to local Drug and Alcohol Action 
Teams (DAATs) and to Primary Care Trusts.  
 
np-SAD Contribution to UK Early Warning System 
In addition to its routine surveillance activities, the Programme also 
provides real-time information on the emergence of novel substances or 
new ways of taking existing substances to the UK Early Warning System 
and the Advisory Council on the Misuse of Drugs (ACMD). This information 
comes both from notifications of deaths and from „alerts‟ or other 
information provided by the various agencies and networks, national and 
international, with which the Programme maintains contacts. Through 
these channels (including coroners, forensic toxicologists, DAATs, and the 
Scottish Crime  & Drug Enforcement Agency), the Programme became 
aware of the emerging issue of the use of various synthetic cathinones and 
similar substances, and of their potential adverse health consequences. It 
was decided to take a pro-active approach to monitor the situation 
especially in respect of the potential role of these new substances in 
causing or contributing to death. 
 
Provision of information to the ACMD 
The np-SAD provided information to the ACMD for its consideration of 
mephedrone and other cathinones. This information was included in the 
ACMD‟s report to the Home Secretary at the end of March 2010. Regular 
updates have been provided to the ACMD Secretariat. The present update 
was invited by the Chair of the ACMD Working Group on “Novel 
Psychoactive Substances” to provide a summary of what the np-SAD 
understands is the current situation. Unfortunately, Department of Health 
funding for this programme was terminated in August 2010, depriving 
ACMD of continuing input on the rapidly changing figures on drug-
associated deaths. The Office for National Statistics can provide some 
information, but on a much slower time frame, on a different counting 
basis, and only for England & Wales. The ACMD have made 
representations to the Department of Health of the importance of this 
programme in informing on the harmfulness of drugs old and new, and 
hope that the evidence can still be collected.   
 
The following information on suspected drug deaths involving mephedrone 
is the situation as known on 20 October 2011 (see annex c table 1) and 
serves as an example of np-SAD input. A number of limitations need to be 
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borne in mind: (a) remaining 'positive' cases are awaiting further inquiries 
or inquest; (b) not all suspected cases may have been identified; several 
deaths have been reported for which the inquests have yet not been 
completed; (c) the fact that mephedrone may have been involved in death 
cannot be confirmed until the relevant coroner or Procurator Fiscal has 
concluded her/his inquest or other formal inquiry; and (d) the presence of 
mephedrone in post mortem toxicology does not necessarily imply that it 
caused or contributed to a death. 
 
Table 1: Number of suspected and confirmed cases of mephedrone-
related deaths, UK and Islands, as at 20 October 2011 
 
Region No of 
suspect
ed 
cases 
No of 
cases 
with 
complet
ed legal 
process 
No of 
cases 
positive 
for 
mephedr
one 
No of cases 
negative for 
mephedrone 
No of 
cases 
awaitin
g 
toxicol
ogy 
results 
No of 
confirme
d cases 
where 
mephedr
one 
caused/ 
contribut
ed to 
death 
Englan
d 
95 45 66 20 (but 
several 
positive for 
other 
methcathino
nes) 
9 29 (5 
forms 
awaited) 
Wales 4 1 4 0 0 1  
Scotla
nd 
16 9 12 3 1 6 
Northe
rn 
Ireland 
9 6 4 2 3 3  
Guerns
ey 
2 2 1 2 0 2 
Jersey 0 0 0 0 0 0 
Isle of 
Man 
1 1 1 0 0 1 (form 
awaited) 
Total 127 64 88 29 13 42 (6 
forms 
awaited) 
Notes: The toxicology results for some suspected cases still remain to be 
ascertained 
 
The evolution of cases with toxicology positive for mephedrone and deaths 
where the substance has been confirmed as causing or contributing to 
death is shown in the following figure. There are some cases for which 
information is not yet available.    
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Figure 1: Evolution of cases with confirmed positive toxicology for 
mephedrone, based on returned np-SAD forms as of 20 October 2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
According to press and media reports, there are concerns by parents of 
young people who appear to have committed suicide, typically by hanging, 
that mephedrone may have contributed to them feeling low or depressed. 
At least 19 inquests have concluded such a link. These reports come from 
all parts of the UK. In these cases, mephedrone appears to act in similar 
ways to cocaine, MDMA and amphetamine. np-SAD has recorded 14 
deaths from hanging following the consumption of these substances. 
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